The QualityStocks Daily Monday, March 11th, 2019

Today's Top 3 StockMarketWatch

StockMarketWatch (DCAR) +664.17%

MarketClub Analysis (GLBS) +92.34%

QualityStocks (BPTH) +54.48%

The QualityStocks Daily Stock List

Golden Leaf Holdings Ltd. (GLDFF)

Stockhouse, Silicon Investor, Market Screener, Marketwired, Tip Ranks, The Seed Investor, InvestorX, Pot Stock News, InvestorsHub, Daily Marijuana Observer, Simply Wall St, MarketWatch, and Infront Analytics reported previously on Golden Leaf Holdings Ltd. (GLDFF), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Golden Leaf Holdings Ltd. is one of the largest cannabis oil and solution providers in North America. In addition, it is a leading cannabis business in Oregon. Golden Leaf has expertise in extracting, refining, marketing, and selling cannabis oil. Golden Leaf Holdings has its corporate office
in Toronto, Ontario. The Company’s shares trade on the OTC Markets Group’s OTCQB.

Golden Leaf Holdings is a foremost cannabis products company built around recognized brands. The Company has operations in many jurisdictions including Oregon, Nevada and Canada. It cultivates, extracts, manufactures and distributes its products through its branded Chalice Farms retail dispensaries and via third party dispensaries.

Golden Leaf’s Canadian subsidiary is Medical Marijuana Group (MMG).  MMG's genetic portfolio includes a strain that holds the highest CBD concentrations in Canada.  MMG was granted a cultivation license from Health Canada in November of 2017 for its state-of-the-art grow facility in Ontario. It began cultivation activities in early 2018.

Golden Leaf’s brands include Golden, Left Coast Connection, and Chalice Farms. Since opening in 2014, Chalice Farms has served the greater Portland, Oregon community with its chain of dispensaries selling its line of premium edibles.

Golden Leaf announced this past November the launch of its edible product line of cannabis infused fruit chews to the Nevada market under the “Golden” brand. In Nevada, Golden Leaf sells a range of ethanol-extract distillate, oils and distillate blends under the Golden Private Stash, RSO-Go and Jackpot brands. Its products now sell wholesale in about 40 percent of dispensaries in Nevada.

Last month, Golden Leaf Holdings announced the appointment of Ms. Karyn O. Barsa as its new Chief Financial Officer (CFO), effective February 4, 2019. In her role as CFO, Ms. Barsa will lead the Company’s financial operations. She will be responsible for managing liquidity, balance sheet risk, and capital market transactions to ensure Golden Leaf remains well positioned to capitalize on growth opportunities. She will report directly to Mr. William Kulczycki, Chief Executive Officer and President of Golden Leaf Holdings.

Golden Leaf Holdings Ltd. (GLDFF), closed Monday's trading session at $0.100195, down 2.25%, on 219,824 volume with 72 trades. The average volume for the last 3 months is 550,144 and the stock's 52-week low/high is $0.064/$0.27.

chart

ProMIS Neurosciences, Inc. (ARFXF)

Insider Financial, Uptick Newswire, Dividend Investor, Capital Cube, Penny Stock Hub, 4-Traders, Streetwise Reports, Stockhouse, TradingView, Investopedia, Wallmine, InvestorsHub, MarketWatch, and OTC Markets reported previously on ProMIS Neurosciences, Inc. (ARFXF), and today we choose to report on the Company, here at the QualityStocks Daily Newsletter.

ProMIS Neurosciences, Inc. focuses on discovering and developing precision medicine therapeutics to treat neurodegenerative diseases, in particular Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS) and Parkinson's disease (PD). The Company’s lead product is PMN310 in Alzheimer’s disease. ProMIS Neurosciences has offices in Toronto, Ontario and Cambridge, Massachusetts. The Company lists on the OTC Markets Group’s OTCQB.

ProMIS Neurosciences’ proprietary target discovery engine is based on the use of two complementary techniques. The Company applies its thermodynamic, computational discovery platform-ProMIS™and Collective Coordinates - to predict novel targets known as Disease Specific Epitopes (DSEs) on the molecular surface of misfolded proteins. Utilizing this unique precision medicine approach, ProMIS is developing novel antibody therapeutics and specific companion diagnostics for AD and ALS.

The Company uses its proprietary technology platform to create highly selective antibodies. Its lead programs are following a “best in class” strategy targeting Amyloid beta in Alzheimer’s disease, with advantages over ”first in class” therapy from Biogen (aducanumab).

ProMIS’ PMN310 is on course to further confirm differentiation from likely “first in class” Biogen’s aducanumab. Furthermore, PMN310 is on course to start clinical trials in 2019 and potentially superior clinical data versus aducanumab in late 2021 soon after aducanumab expected approval.

For Alzheimer’s disease, ProMIS Neurosciences’ most advanced priority program, three validated product candidates have been designated. These are PMN310, PMN350, and PMN330. In January of 2018, ProMIS announced that its lead product candidate for Alzheimer's disease (AD), PMN310, showed absence of binding to amyloid beta (Aβ) plaque in and around blood vessels in AD brain samples in a preclinical study directly comparing PMN310 to other Aβ-directed antibodies.

ProMIS Neurosciences announced this past October the identification of novel targets on misfolded, pathological forms of tau. It said that the development of antibody therapeutics that selectively block these toxic forms of tau constitutes an exciting approach to treating Alzheimer's and other neurodegenerative diseases.

Last month, ProMIS Neurosciences announced the identification of a number of monoclonal antibody (mAb) drug candidates, which selectively target toxic forms of the protein alpha-synuclein, considered to be a root cause of Parkinson's disease (PD).

Dr. James Kupiec, the Company’s Chief Medical Officer, stated, "We used our proprietary discovery platform to generate several antibody drug candidates for Parkinson's disease that precisely target only the toxic forms of alpha-synuclein. Selectivity represents the essential feature of a successful antibody therapy, for it is critical that treatment not hinder normal forms of alpha-synuclein that play an important functional role in the brain.”

ProMIS Neurosciences, Inc. (ARFXF), closed Monday's trading session at $0.262, up 2.54%, on 73,200 volume with 37 trades. The average volume for the last 3 months is 125,175 and the stock's 52-week low/high is $0.138/$0.415.

chart

Azucar Minerals Ltd. (AXDDF)

Tip Ranks, Streetwise Reports, GuruFocus, Morningstar, Investorx, Stockwatch, The Street, Penny Stock Hub, Barchart, Dividend Investor, Stockhouse, MarketWatch, InvestorsHub, Market Screener, 4-Traders, and Interactive Brokers reported earlier on Azucar Minerals Ltd. (AXDDF), and today we report on the Company, here at the QualityStocks Daily Newsletter.

Azucar Minerals Ltd. is an exploration company with a mandate to thoroughly explore the El Cobre project in Veracruz, Mexico. The Company was formerly known as Almadex Minerals Limited. It changed its name to Azucar Minerals Ltd. in May of last year. Azucar Minerals has its corporate office in Vancouver, British Columbia. The Company lists on the OTC Markets’ OTCQX.

Azucar Minerals holds a 100 percent interest in the El Cobre project, subject to Net Smelter Returns (NSR) royalty interests, assuming production from the property exceeds 10,001 tonnes per day of ore, totaling 2.25 percent which can be reduced to 2.0 percent through the payment of US$3.0 million.

The El Cobre project is a roughly 7,300 Ha property. It covers manifold gold-rich porphyry targets, as demonstrated by recent drilling. Azucar Minerals is fully permitted for drilling and funded for an active exploration campaign this year. El Cobre is 75 kilometers northwest of Veracruz city.

The El Cobre project is road accessible. It is situated in an area of first-rate infrastructure, close to a power plant, highways and rail systems. The project has four copper-gold porphyry targets - Encinal, El Porvenir, Norte, and Villa Rica. The porphyries are defined by distinct copper-gold soil anomalies, discrete positive magnetic features, and an extensive shallow IP chargeability anomaly.

In late February, Azucar Minerals announced that it hit 18.00 M of 0.51 g/t Au and 0.43% Cu at the Villa Rica Target, El Cobre Project, Mexico. The Company announced results from its continuing drilling program at the El Cobre porphyry copper-gold project in Veracruz State. Drilling is now taking place at the Villa Rica target, the Norte zone and in the Porvenir/Encinal area.

The results reported are from the Villa Rica area, a large (approximately 2.5 by 1 km) altered area defined by high magnetics responses with local zones of elevated copper, gold and molybdenum in soil. Hole EC-18-052 and 054 were drilled underneath the earlier announced hole EC-17-037.

Both EC-18-052 and 54 hit porphyry mineralization (EC-18-052 hit 18.00 meters that averaged 0.51 g/t gold and 0.42% copper). The intercepts in the three holes suggest that the mineralized intrusive has been clipped and the drilling has not cut across the potential porphyry body so far. More drilling is taking place in the Villa Rica area based on these results.

Azucar Minerals Ltd. (AXDDF), closed Monday's trading session at $0.221, down 7.69%, on 28,774 volume with 19 trades. The average volume for the last 3 months is 58,368 and the stock's 52-week low/high is $0.215/$1.29.

chart

BioElectronics Corporation (BIEL)

Microcap Daily, Central Charts, Pink Investing, Uptick Newswire, Wallet Investor, Emerging Growth, Clay Trader, Street Register, Stockhouse, MarketWatch, Investors Hangout, StreetInsider, Barchart, Biospace, InvestorsHub, Market Screener, and Morningstar reported beforehand on BioElectronics Corporation (BIEL), and today we choose to report on the Company, here at the QualityStocks Daily Newsletter.

BioElectronics Corporation is a leader in non-invasive electroceuticals. The Company is the maker of an industry leading family of disposable, drug-free, pain therapy devices. Its unique medical devices safely and effectively treat chronic and acute pain via an innovative mechanism of non-invasive sub-sensory neuromodulation. BioElectronics has its corporate office in Frederick, Maryland.

BioElectronics’ products include RecoveryRx® and ActiPatch®. RecoveryRx® uses pulsed electromagnetic therapy to lessen pain and inflammation resulting in accelerated patient recovery and improved comfort. For medical professionals, the RecoveryRx® medical device provides a safe and cost-effective pain management therapy.

ActiPatch® provides advanced long-lasting chronic pain relief using Electromagnetic Pulse Therapy. It is a new and clinically proven drug free technology in the battle against chronic pain. 

The Company’s products also include Smart Insole™, Allay® Menstrual Pain Relief, and HealFast® Veterinary Pain Relief. HealFast® Therapy is a drug-free therapy for horses, cats and dogs. It decreases swelling and pain while it hastens the healing of muscle and tendon injuries, sores, and incisions.

Allay® is an award-winning drug-free micro medical device. It uses Electromagnetic Pulse Therapy to lessen menstrual pain and discomfort. The Smart Insole™ consists of Electro-Pulse micro medical devices. These are embedded in comfortable heel gel inserts.

Last month, BioElectronics announced that two Traditional 510(k) Premarket Notification applications were filed with the U.S. Food and Drug Administration (FDA). These applications were for the ActiPatch® and RecoveryRx® medical devices for market clearances of “over-the-counter adjunctive treatment of musculoskeletal pain in women”, and “over-the-counter adjunctive treatment of postoperative pain”, respectively.

Mr. Keith Nalepka, VP of Sales/Marketing, said, “Obtaining musculoskeletal and postoperative pain clearances will make ActiPatch and RecoveryRx devices available to more than 100 million Americans seeking safe, drug-free pain relief.”

Last week, BioElectronics announced the start of a clinical study investigating the efficacy of ActiPatch in treating chronic lower back pain. The goals of this additional back pain study are to support Mundipharma’s Australia and New Zealand sales and marketing, provide local economic data for product reimbursement, and to document ActiPatch’s effectiveness on central sensitization pain.

This study is being conducted by the Pain Management Center of the prestigious Royal Prince Alfred Hospital in Sydney, Australia. The principal investigator (PI) leading the study is Mr. Graeme Campbell, a physiotherapist, supported by his team of physicians and clinical researchers.

BioElectronics Corporation (BIEL), closed Monday's trading session at $0.0009, up 28.57%, on 24,407,855 volume with 44 trades. The average volume for the last 3 months is 43,440,624 and the stock's 52-week low/high is $0.0005/$0.005.

chart

Fortescue Metals Group Limited (FSUMF)

Trading View, The Street, MarketWatch, Investor Village, Wallet Investor, Marketbeat, Equity Clock, 4-Traders, Morningstar, OTC Markets, Current Charts, InvestorsHub, YCharts, and Dividend Investor reported earlier on Fortescue Metals Group Limited (FSUMF), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

OTCQX-listed, Fortescue Metals Group Limited is a global leader in the iron ore industry. The Company has grown to be one of the largest international iron ore producers. Currently, Fortescue produces 170 million tonnes of iron ore per annum. Fortescue Metals Group is based in East Perth, Western Australia.

Fortescue is the first company in Western Australia to control a railway from outside an area of operation. It wholly owns and operates its purpose designed rail and port facilities. The Company’s railway covers 620 kilometers of track. In addition, Fortescue is the first company worldwide to use CAT autonomous haulage technology on a commercial scale.

Fortescue Metals continues to undertake early stage, low cost exploration on coppergold prospective tenements in South Australia and New South Wales. Furthermore, the Company has assessed high potential, early stage exploration tenements in Ecuador, where it was granted 32 exploration areas.

Fortescue owns and operates integrated operations encompassing three mine sites in the Pilbara, the five berth Herb Elliott Port in Port Hedland, and the fastest, heavy haul railway in the world. At present, the Company supplies 17 per cent of China’s seaborne iron ore.

The Company has expanded autonomous haulage at Chichester Hub. The expansion of its autonomous haul fleet has marked a significant milestone, with the first trucks fitted with Autonomous Haulage Technology (AHS) now in operation at Christmas Creek. The Chichester Hub in the Chichester Ranges, comprising the Cloudbreak and Christmas Creek mines, has an annual production capacity of 100mtpa from three Ore Processing Facilities (OPF). The conversion of about 100 haul trucks at the Chichester Hub will see Fortescue Metals become the first iron ore operation globally to have a fully autonomous fleet.

Fortescue Metals has its Iron Ore Projects. Its Iron Bridge Project is 100 kilometers south of Port Hedland. This is a JV between Fortescue Metals Group, Taiwan’s Formosa Group, and China’s Baosteel Group, incorporating the world class North Star and Glacier Valley Magnetite ore bodies. Moreover, Fortescue’s Iron Ore Projects include the Firetail Replacement Project. Firetail is an important aspect of the Fortescue Blend product.

Fortescue’s operations include The Solomon Hub in the Hamersley Ranges. The Solomon Hub is 60 kilometers north of Tom Price and 120 kilometers to the west of Fortescue Metals’ Chichester Hub.

In South America, the Company continues to assess exploration and development opportunities throughout, including Ecuador, Colombia and Argentina. Thirty-two exploration concessions were awarded in Ecuador and initial evaluation of potential for porphyry copper deposits began. A further 64 applications were lodged in Colombia for exploration concessions in areas that are copper and gold prospective.

Fortescue Metals Group Limited (FSUMF), closed Monday's trading session at $4.55, even for the day, on 200 volume. The average volume for the last 3 months is 8,896 and the stock's 52-week low/high is $2.53/$4.73.

chart

Glance Technologies, Inc. (GLNNF)

Connecting Investor, Stock Invest, Wallet Investor, Trading View, InvestorsHub, Emerging Growth, Stockhouse, GuruFocus, Evergreen Caller, MarketWatch, InvestorsHub, and Insider Financial reported previously on Glance Technologies, Inc. (GLNNF), and we report on the Company as well, here at the QualityStocks Daily Newsletter.

Glance Technologies, Inc. owns and operates Glance Pay. This is a streamlined payment system. Glance Pay transforms how smartphone users choose where to dine, order food and drink, settle bills, access digital receipts, earn premier rewards, and interact with merchants. With the Glance Pay mobile payment application (app), there is no set up or cancellation fees and no system integration or connections required. OTCQB-listed, Glance Technologies is based in Vancouver, British Columbia.

The Glance Pay mobile payment system consists of proprietary technology. This technology includes user apps available for free downloads in IOS (Apple) and Android formats, a merchant manager apps, a large-scale technology hosting environment with sophisticated anti-fraud technology, and very fast payment processing.

The Company offers targeted in-app marketing, social media marketing, customer feedback, in-merchant messaging, and custom rewards programs. The Glance Pay mobile payment app works for full service restaurants, quick serve restaurants (QSRs), retail, and more. Furthermore, the app features easy activation and training, easy automatic accounting and reconciliation, and quick payment deposits.

Glance Technologies’ intention is to apply components of its anti-fraud technology to cryptocurrencies. This is to lessen the risk associated with converting traditional currencies to and from cryptocurrencies. Glance is pursuing opportunities to license its earlier acquired BlockImpact cryptocurrency and blockchain platform as a white label solution.

Glance Technologies has launched its new Pay With Bitcoin feature. Pay With Bitcoin permits Glance Pay users to pair their cryptocurrency wallet with their Glance Pay account, and then buy Glance Dollars with Bitcoin. Glance Dollars represent a credit that can be spent quickly at participating merchants within the Glance Pay ecosystem.

Recently, Glance Technologies announced it officially launched its ‘Real-Time Bill™’ feature to the public at select locations. Numerous other locations are lined up for launch. ‘Real-Time Bill™’ is a pioneering new feature that allows users to view and pay their bill in real time directly from the Glance Pay™ App whenever they are ready to leave, without needing to wait for a paper bill.

This app identifies the user’s bill based on Quick Response (QR) codes or Near-field communication (NFC) tags at their table. The app accesses and settles the appropriate bill in real-time from the merchant’s point of sale (POS) system. ‘Real-Time Bill™’ considerably improves the experience for consumers. Moreover, it enables restaurants to turn their tables over much quicker. The result is greater revenue, lower staffing costs, as well as more satisfied customers.

Glance Technologies, Inc. (GLNNF), closed Monday's trading session at $0.122683, up 2.24%, on 136,847 volume with 38 trades. The average volume for the last 3 months is 255,013 and the stock's 52-week low/high is $0.074/$0.68.

chart

Lion One Metals Limited (LOMLF)

Stock Twits, Investors Hub, Junior Mining Network, MarketWatch, Morningstar, Top Stocks, Barchart, Stockhouse, OTC Markets, Canadian Mining Report, ‎Investor Ideas, StreetWise Reports, TradingView, Mining Atlas, and Stock World reported previously on Lion One Metals Limited (LOMLF), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Lion One Metals Limited focuses on advancing to production at its 100 percent owned and fully permitted high grade underground Tuvatu Gold Project. Tuvatu is situated on the island of Viti Levu in the Republic of Fiji. Tuvatu is the largest undeveloped gold project in Fiji. Moreover, it is one of the highest-grade gold projects anywhere in the world. Lion One Metals is headquartered in Vancouver, British Columbia. In addition, the OTCQX-listed Company has offices in Fremantle, Australia and in Waimalika, Nadi, Republic of Fiji.

Lion One Metals is focused on building production of 100,000 oz. per year over 10 years. The Company holds a 200 km² exploration license package encompassing the entire Navilawa volcano, with the Tuvatu mining lease at its center.

Lion One Metals is centering on cost effective and environmentally responsible construction, development, and advancement of Tuvatu towards production. This is tied with exploration of its district-scale license areas covering the highly prospective and underexplored Navilawa volcano. It is advancing Tuvatu as a near-term production opportunity with exploration upside in the southwest Pacific Ring of Fire.

The Company has modeled Tuvatu for exploration after regional giants in the low sulphidation family of high grade epithermal gold deposits. This includes Porgera and Lihir in Papua New Guinea, and Vatukoula in Fiji, which boast production of over 35 million ounces of gold in similar alkaline volcanic settings.

The independent Tuvatu NI 43-101 PEA technical report by Mr. Ian Taylor, BSc (Hons) MAusIMM (QP) dated June 1, 2015 foresees a low cost underground gold mining operation producing 352,931 ounces of gold over 7 years at head grades of 11.30 g/t Au, and cash costs of US$567 per ounce with all-in sustaining cost (AISC) of US$779 per ounce.

Lion One Metals has not based a production decision on a Feasibility Study (FS) of mineral reserves demonstrating economic and technical viability. Thus, there is increased uncertainty and economic and technical risks associated.

Last month, Lion One Metals announced a partnership with Swiss-based clean energy provider the meeco Group to construct and install a hybrid solar/diesel power plant for the Company's 100 percent owned and fully permitted Tuvatu Gold Project. Lion One Metals will be a 50 percent shareholder of a Special Project Vehicle (SPV) by way of an agreed buy-in structure.

Lion One Metals will use meeco's 7 MW peak "sun2live" solar power generation system paired with diesel generators. This is to generate up to 11 MW peak power production providing a continuous 24-hour source of power for the Tuvatu gold mine and processing plant.

Lion One Metals announced at the beginning of this month that Dr. Quinton Hennigh was appointed as Technical Advisor for the Company's Tuvatu Gold Project in Fiji. Dr. Hennigh is an internationally-renown economic geologist, with more than 25 years of exploration experience and expertise with major gold mining companies.

Lion One Metals Limited (LOMLF), closed Monday's trading session at $0.4623, up 3.74%, on 57,800 volume with 14 trades. The average volume for the last 3 months is 11,196 and the stock's 52-week low/high is $0.244/$0.615.

chart

AEON Global Health Corp. (AGHC)

Amigo Bulls, Stockhouse, InvestorsHub, YCharts, TradingView, The Street, Stock Target Advisor, Stockopedia, Penny Stock Hub, Stockwatch, Simply Wall St, Zacks, Stockflare, Dividend Investor, and Investors Hangout reported earlier on AEON Global Health Corp. (AGHC), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

AEON Global Health Corp., together with its subsidiaries, provides an array of clinical laboratory testing services in the U.S. It offers diagnostic services in Cancer Genomics, Toxicology, Pharmacogenomics, as well as Health Technology Applications. The Company previously went by the name Authentidate Holding Corp. It changed its name to AEON Global Health Corp. in January of this year. OTCQB-listed, AEON Global Health is based in Gainesville, Georgia.

The Company’s main business emphasis is providing a “personalized medicine” approach to laboratory testing services. This is to provide customers with actionable medical information. AEON is the fastest growing clinical lab and healthcare services organization in the U.S. It is first in healthcare technology research and development (R&D) where its proprietary methodologies provide expedited and highly accurate urine and oral fluid (saliva) test results.

AEON is an innovator in the genomic testing area. It has a wide-ranging menu of genetic tests and a pipeline of additional molecular-based tests in development. The Company provides post contract customer support services. The design of AEON’s Telehealth Solutions is to improve outcomes and decrease hospital readmission through helping clinicians closely monitor patients with chronic illnesses including CHF, COPD and Diabetes.

AEON Clinical Labs services include Cancer Genomics, Pharmacogenomics, Toxicology, and Women’s Health. Health Technologies services include Inscrybe®. This is a secure and simple interface. Inscrybe® enables physicians, nurses, hospital staff, and external care facilities or health insurers to send, receive, sign, and track healthcare records, supporting documents, patient discharge orders and referrals or lab results and images on the web or through electronic fax instead of transferring paper.

AEON Global Health has agreed with Sabal Therapeutics, LLC to be the primary laboratory marketer of Naprosyn®. This is the branded naproxen oral suspension USP. With this agreement, AEON will become the exclusive clinical laboratory marketing representative of Sabal Therapeutics. It will market the drug alongside of its industry-leading drug monitoring service.

Regarding Toxicology Testing, AEON Global Health offers accurate and quick quantitative testing of drug metabolite levels in urine and oral fluids. The Company’s testing encompasses greater than 80 analytes and metabolites. Its HPLC-tandem mass spectrometry can analyze wider molecular weight and polarity ranges of analytes, providing better selectivity and sensitivity.

AEON Global Health Corp. (AGHC), closed Monday's trading session at $0.43, up 20.87%, on 200 volume with 2 trades. The average volume for the last 3 months is 4,595 and the stock's 52-week low/high is $0.282/$1.25.

chart

HealthLynked Corp. (HLYK)

OTC Markets and InvestorsHub reported on HealthLynked Corp. (HLYK), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

HealthLynked Corp. centers on improving healthcare services for patients and physicians. Its technology lessens wait times with online scheduling of appointments and real-time appointments by local providers. Furthermore, the Company’s technology provides easy access to an individual’s and their family’s updated medical records. HealthLynked has its corporate headquarters in Naples, Florida.

The Company concentrates on improving healthcare through connecting patients with their healthcare providers. The HealthLynked Network focuses on the efficient, secure exchange of medical information between patients and their healthcare providers. The cloud-based HealthLynked Network lets patient's medical records move with them. This is so one’s medical records are not fragmented in manifold healthcare systems and/or EHR (Electronic Health Record) systems.

The HealthLynked Healthcare Summary permits patients to maintain a complete medical profile in coordination with physicians. All information is systematically categorized. As a result, physicians have a total overview of patient health without them having to fill unnecessary paperwork.

HealthLynked profile information safeguards that doctors don't prescribe potentially harmful medications in case a patient forgets to mention one or more present medications while talking to their doctor. Moreover, the HealthLynked Healthcare Summary page enables patients to keep their medical records updated. This helps physicians to be more productive and provide valid medical care. 

In August, HealthLynked announced the release of its latest software upgrade to the Company’s network, which allows physicians to connect with other physicians across the country. The new service facilitates and encourages several critical interactions among healthcare providers that can substantiallly improve patient care.

This application enables healthcare providers to “lynk” to one another through HealthLynked’s online directory of more than 880,000 healthcare providers in the U.S. Upon being connected, physicians can communicate through online messages or in real time through the Company’s online chat feature. They can also can share files, medical articles and can engage in group discussions with numerous physicians.

Last week, HealthLynked announced the launch of its mobile app for Android™ mobile devices, which connects patients (users/members) with their healthcare providers. Its application permits members to access their HealthLynked profile and medical information while in transit, eliminating redundant paperwork and the need to carry physical medical records and insurance cards to physician office visits.

HealthLynked Corp. (HLYK), closed Monday's trading session at $0.29, down 0.68%, on 317,676 volume with 94 trades. The average volume for the last 3 months is 187,145 and the stock's 52-week low/high is $0.07/$0.65.

chart

NXT Energy Solutions, Inc. (NSFDF)

Serious Traders, SmarTrend Newsletters, Vantage Wire, StockOoodles, and Streetwise Reports reported previously on NXT Energy Solutions, Inc. (NSFDF), and we highlight the Company as well, here at the QualityStocks Daily Newsletter.

NXT Energy Solutions, Inc. is a technology business.  The Company’s proprietary Stress Field Detection (SFD®) survey system uses quantum-scale sensors to detect gravity field perturbations in an airborne survey method that can be used onshore and offshore to remotely identify areas with exploration potential for traps and reservoirs. Established in 1994, NXT Energy Solutions is headquartered in Calgary, Alberta.   

The Company’s unique  geophysical service is for the upstream oil & gas industry.  SFD® is environmentally friendly. It is unaffected by ground security issues or difficult terrain.  SFD® is an airborne tool. It provides information on areas favorable to fluid entrapment in the sedimentary column. The SFD® survey is complementary to existing geophysical methods, especially seismic programs.

NXT Energy Solutions provides its clients with an effective and reliable method to lessen time, costs, and risks related to exploration. The  SFD® survey system allows its clients to focus their hydrocarbon exploration decisions concerning land commitments, data acquisition expenditures, and prospect prioritization on areas with the greatest potential.

SFD®, in pre-seismic applications, can produce high-potential prospect leads in large underexplored regions. In post-seismic applications, SFD® can prioritize seismic prospects based on their reservoir potentials. 

In January 2018, NXT Energy Solutions announced the first worldwide patent of the Stress Field Detection (SFD®) Technology and the development of a new generation of sensors, which will enhance the Company’s ability to provide higher quality survey results. NXT is negotiating commercial contracts for the application of its proprietary SFD® oil & gas exploration method with governments, national oil companies, and other industry participants.

Recently, NXT Energy Solutions announced its financial and operating results for the quarter-ended June 30, 2018. No survey Revenues were recorded for the first two quarters of 2018. A Net Loss of $1.96 million was recorded for the three months ended June 30, 2018.  A Net Loss of $3.92 million was recorded for the six months ended June 30, 2018.

NXT Energy Solutions, Inc. (NSFDF), closed Monday's trading session at $0.278, up 11.20%, on 39,000 volume with 13 trades. The average volume for the last 3 months is 15,123 and the stock's 52-week low/high is $0.15/$1.05.

chart

Humanigen, Inc. (HGEN)

AmigoBulls, TradingView, OTC Markets, Investopedia, InvestorsHub, Barchart, Investors Hangout, and Financial Times reported on Humanigen, Inc. (HGEN), and we report on the Company as well, here at the QualityStocks Daily Newsletter.

Humanigen, Inc. focuses on advancing medicines for patients with neglected and rare diseases via innovative, accelerated business models. Lead compounds in its portfolio include the proprietary monoclonal antibodies, lenzilumab and ifabotuzumab. Derived from its Humaneered® platform, lenzilumab and ifabotuzumab are lead compounds in the portfolio of monoclonal antibodies with first-in-class mechanisms. OTCQB-listed, Humanigen is headquartered in Brisbane, California.

The Company pursues unique science to develop its proprietary monoclonal antibodies for immunotherapy and oncology treatments.   Lenzilumab has potential for treatment of different rare diseases. These include hematologic cancers such as chronic myelomonocytic leukemia (CMML),  and juvenile myelomonocytic leukemia (JMML).  Lenzilumab is a Humaneered®  recombinant monoclonal antibody. It neutralizes soluble granulocyte-macrophage colony-stimulating factor (GM-CSF), which is a critical cytokine that drives the growth of certain hematologic malignancies.

The other key asset in Humanigen’s monoclonal antibody portfolio, ifabotuzumab, has been dosed in the first patient in an investigator-sponsored Phase 0/1 radio-labeled imaging trial in glioblastoma multiforme (GBM). Ifabotuzumab is a first-in-class, monoclonal antibody. It targets the EphA3 receptor tyrosine kinase created utilizing Humanigen’s proprietary Humaneered® technology.  

Lupagen announced this past May the intent to explore the development of a bedside, point-of-care delivered CAR-T therapy with Humanigen. It is developing first-in-class cell and gene therapy delivery technologies for CAR-T, gene editing and immunotherapy products.

Lupagen and Humanigen are planning work to investigate the potential of a bedside CAR-T therapy created from Humanigen's Ifabotuzumab. Lupagen, Inc. is a privately held early stage medical device company.

Last week, Humanigen announced positive topline results from a preclinical study demonstrating that use of its proprietary anti-GM-CSF antibody, lenzilumab, along with CD19 targeted chimeric antigen receptor T-cell therapy (CART19) lessens neurotoxicity (NT) and cytokine release syndrome (CRS) and enhances CART19 proliferation and effector functions. A complete data set from this study has been submitted for presentation to the 2018 Annual Meeting of the American Society of Hematology, which will take place this December.

Humanigen, Inc. (HGEN), closed Monday's trading session at $1.25, down 4.73%, on 28,346 volume with 15 trades. The average volume for the last 3 months is 8,945 and the stock's 52-week low/high is $0.27/$1.544.

chart

BioLargo, Inc. (BLGO)

Tiny Gems, Stock News Now, Promotion Stock Secrets, SECFilings, FeedBlitz, Equities, TopPennyStockMovers, SmallCapVoice, and Penny Sleuth reported previously on BioLargo, Inc. (BLGO), and today we report on the Company, here at the QualityStocks Daily Newsletter.

BioLargo, Inc. delivers practical solutions for clean water, clean air, and advanced wound care. It delivers technology-based products, which help solve some of the globe’s most important problems that threaten water, food, agriculture, healthcare and energy. BioLargo is an innovator of sustainable science and technology and a full-service environmental engineering company. BioLargo has its corporate office in Westminster, California. The Company’s shares trade on the OTCQB. 

BioLargo’s subsidiary is BioLargo Water, Inc.  BioLargo Water showcases the Advanced Oxidation Systems, including its AOS Filter. This product in development is purposely designed to eliminate common, troublesome, and toxic contaminants in water in a fraction of the time and expense of present technologies.

The BioLargo® AOS Filter is the Company’s featured AOS Filter system. The BioLargo® AOS Filter extends the life of filtration systems, reduces corrosion, and conserves chemistry. The Company’s Canadian subsidiary, BioLargo Water, Inc. started a prototype development project for its AOS Filter technology.

The BioLargo® AOS Filter facilitates ongoing and scalable treatment with maximum efficiency using GRAS components to convert contaminates to H2O and CO2.  It destroys hard to get contaminates and disinfects quickly and completely. The BioLargo® AOS Filter is complementary with manifold filter systems.

BioLargo’s subsidiary, Odor-No-More, Inc., features award-winning products serving the pet, equine, military supply, and consumer markets. This includes the Nature's Best Solution® and Deodorall® brands. CupriDyne® Clean Industrial Odor Eliminator is made by Odor-No-More.  Odor-No-More has signed what are known as national purchasing or national supply agreements with three leading U.S. waste handling enterprises.

BioLargo’s subsidiary, Clyra Medical Technologies, Inc., concentrates on advanced wound care management. Furthermore, BioLargo owns a 50 percent interest in the Isan System. This system was honored with a "Top 50 Water Company for the 21st Century" award by the Artemis Project, now under license to Clarion Water, Inc.

Last week,  BioLargo announced that the Innovative Conservation Program (ICP) granted funding to support a pre-commercial pilot water treatment study project at the Joshua Tree Brewery. This brewery is under construction in Joshua Tree, California, and scheduled to open in late 2018.

This pilot project will feature BioLargo’s Advanced Oxidation System (AOS) and Aquacycl’s BioElectrochemical Treatment Technology (BETT™) to demonstrate that these combined technologies can provide effective and cost-efficient treatment of the brewery’s wastewater to meet California discharge standards and avoid regulatory non-compliance. The project’s objective is to allow the wastewater to be used for landscaping irrigation.

BioLargo, Inc. (BLGO), closed Monday's trading session at $0.17, up 0.74%, on 367,061 volume with 91 trades. The average volume for the last 3 months is 112,121 and the stock's 52-week low/high is $0.1615/$0.46.

chart

Thin Film Electronics ASA (TFECF)

Speculating Stocks, Penny Stock Millionaire, Penny Stock Tweets, Stockhouse, TradingView, OTC Markets, Dividend Investor, Wallet Investor, InvestorsHub, The Street and 4-Traders reported on Thin Film Electronics ASA (TFECF), and we also highlight the Company, here at the QualityStocks Daily Newsletter.

Thin Film Electronics ASA provides near field communication (NFC) mobile marketing and smart-packaging solutions by printed electronics technology. The Company offers end-to-end mobile marketing solutions, which feature hardware, label/packaging integration services, and a strong cloud-based software platform.

Thin Film Electronics lists on the OTC Markets Group’s OTCQX. The Company is headquartered in Oslo, Norway. It also has offices in Silicon Valley, Sweden, San Francisco, London, and Shanghai.

Thin Film’s corporate vision is to make everyday items ‘just smart enough’, therefore, effectively extending the traditional boundaries of the IoT to create the Internet of Everything. The Company has 270 patents and patents-pending.

Thin Film’s products include NFC Solutions. NFC involves hardware and software designed with volume production in mind. NFC Solutions is built on highly scalable printed electronics technology. NFC features OpenSense™ Technology - Dual-ID tag with sealed/opened sensor. It also features SpeedTap™ Technology - Single-ID tag.

The Company’s products also include EAS Tags. These are for retailers to strengthen their retail loss-prevention programs with next-generation anti-theft tags. Thin Film’s 8.2MHz tags are compatible with internationally installed infrastructure. Integrated EAS maximizes product availability and minimizes loss. In addition, EAS Tags decrease overhead associated with hard tag application and removal.

Last week, Thin Film Electronics announced a collaboration with Clause, the top provider of “smart” legal contracting technology. Via this collaboration, Clause and Thin Film will use NFC to enable the pairing of physical goods to digital contracts through the tap of a smartphone.

The resulting connection will deliver important functional and efficiency improvements for customers across the Clause “connected contracting” platform. This includes contract creation and management, supply chain administration, and invoice/payment automation. Thin Film will integrate Clause’s connected contracting solution with the CNECT™ Cloud Platform.

Moreover, this solution will position Thin Film’s CNECT™ Blockchain Services as an optional security feature. This will allow customers and partners of both organizations to authenticate products, confirm deliveries, review supply chain routes, and verify the origin of goods.

Thin Film Electronics ASA (TFECF), closed Monday's trading session at $0.04865, up 5.76%, on 52,600 volume with 5 trades. The average volume for the last 3 months is 6,093 and the stock's 52-week low/high is $0.046/$0.308.

chart

Research Solutions, Inc. (RSSS)

NetworkNewsWire, Penny Stock Tweets, Simply Wall St, InvestorPoint, OTC Markets, InvestorsHub, Wall Street Resources, Stockhouse, and Marketbeat reported on Research Solutions, Inc. (RSSS), and today we report on the Company, here at the QualityStocks Daily Newsletter.

Research Solutions, Inc. is an innovator in providing cloud-based solutions for scientific research. The Company is a pioneer in cloud-based SaaS (Software-as-a-Service) research intelligence products and services for research-intensive organizations. Research Solutions has its corporate headquarters in Encino, California. The Company’s shares trade on the OTC Markets Group’s OTCQB.

Research Solutions  has its wholly-owned subsidiary Reprints Desk, Inc. Reprints Desk improves how journal articles and clinical reprints are accessed, procured, and legally used in evidence-based promotions, medical affairs, and scientific, technical, and medical (STM) research.

Reprints Desk and Altmetric LLP previously agreed to integrate Altmetric badges to scholarly content obtained through Reprints Desk's award-winning research retrieval platform Article Galaxy.  Altmetric is a foremost research metrics provider. 

  Reprints Desk signed separate reseller agreements with Ritme and Alfasoft to deliver new tools and services. These tools and services address the total range of knowledge acquisition and information management requirements of researchers in scientific, technical, as well as medical (STM) fields.

Research Solutions’ cloud-based SaaS platform provides customers with on demand access to, and augmented data from, tens of millions of scientific, medical, and technical (STM) documents. This is in addition to tens of millions of articles previously published.

Research Solutions recently appointed two key senior executives to the roles of Chief Sales Officer and Chief Marketing Officer. Mr. Rogier van Erkel, Chief Sales Officer, joins Research Solutions with 12 years of sales management experience at Elsevier, an information and analytics company.

Mr. Yohann Georgel, Chief Marketing Officer, brings to Research Solutions 12 years of marketing experience, most recently serving as Senior Director of Digital Marketing for PrimeSport for more than six years.

Regarding its Preliminary Fiscal 2018 results, Research Solutions expects to report Total Revenue of roughly $28.0 million, up 9 percent versus $25.7 million in fiscal 2017. The Company expects to present its full Fiscal 2018 financial results in September.

Research Solutions, Inc. (RSSS), closed Monday's trading session at $2.30, up 3.60%, on 2,766 volume with 4 trades. The average volume for the last 3 months is 2,366 and the stock's 52-week low/high is $1.25/$2.70.

chart

The QualityStocks Company Corner

Youngevity International, Inc. (NASDAQ: YGYI)

The QualityStocks Daily Newsletter would like to spotlight Youngevity International, Inc. (YGYI).

Youngevity International Inc. (NASDAQ: YGYI), an emerging conglomerate operating in three distinct business segments, this morning announced that it will be presenting at the second annual LD Micro Virtual Conference on Tuesday, March 12 at 4:00 pm EST. To access the presentation, visit http://nnw.fm/5BUxT. To view the full press release, visit: http://nnw.fm/Xnvm0.

Youngevity International, Inc. (NASDAQ: YGYI) is a leading omni-direct lifestyle company offering a hybrid of the direct selling business model that includes e-commerce and the power of social selling. Among the Top 100 Global Direct Selling Companies, Youngevity offers products from the six top selling retail categories: health/nutrition, home/family, food/beverage (including coffee), spa/beauty, apparel/jewelry, and a range of innovative services. Created through the 2011 merger of Youngevity Essential Life Sciences with Javalution® Coffee Company, today’s Youngevity International Inc. is a virtual worldwide Main Street of products and services under one corporate entity that supports a healthy and empowered lifestyle.

Youngevity International is dedicated to improving lifestyles through the universal desires of vibrant health and flourishing economics. Catering to health-conscious consumers, Youngevity believes that combining the best of the direct selling industry with the fundamentals and capabilities of a traditional business model will maximize shareholder value. The company’s Nutritional, Lifestyle and Telecommunications products and services are distributed through a global network of Preferred Customers and Distributors.

Youngevity’s wholly owned CLR Roasters LLC business line offers quality branded and private label coffee to retail stores, office coffee services, hospitality, food services, distributors, convenience, petrol stores and vending businesses. Today, CLR Roasters is the largest coffee provider for cruise lines in North America and the second largest roaster in the state of Florida. Producing a consistent premium product with superior taste, CLR Roasters has earned numerous certifications that demonstrate the company’s commitment to the craft of providing the highest quality coffee products using the best practice standards available.

Youngevity, operating in the direct-selling channel, is rapidly expanding its product and distributor base through acquisitions and mergers under an innovative concept called “the Network Cloud” that provides other direct selling companies with a home base. The company’s YoungevityGO2 mobile distributor app, a new technology-driven web platform supporting expansion of global e-commerce and social selling platforms, is available on Google Play and the App Store. In addition to the Network Cloud concept, Youngevity International owns CLR Coffee Roasters which operates a traditional coffee roasting business offering a JavaFit® gourmet product line that vertically integrates with Youngevity and its growing network of direct marketers.

Youngevity International offers more than 1,000 high quality, technologically advanced products under the following categories:

  • Health and Nutrition
  • Home and Family
  • Food and Beverage
  • Spa and Beauty
  • Fashion
  • Essential Oils
  • Photo and scrapbooking
  • Services for Home and Business

Youngevity International Inc. has compiled a best-in-class management team with a strong track record of success in private and public companies. Steve Wallach, CEO, has nearly two decades of sales and network marketing experience and has successfully guided Youngevity International Inc. to become an international, publicly-traded direct marketing company positioned for worldwide growth. Dave Briskie, president and CFO, has shepherded the company’s development into a fully vertical coffee roasting and distribution company that owns the direct marketing brand JavaFit® and the retail brand, Café La Rica.

Youngevity has also attracted a stunning group of Brand Evangelists who endorse its products. Among these are actress, author and well-known health and wellness activist Marilu Henner; former NBA basket player, Mike “Stinger” Glenn; former NFL wide receiver Drew Pearson; “Greatest Natural Bodybuilder in the World” Gene Nelson; and WNBA champion, Olympic gold medalist Delisha Jones.

Youngevity International, Inc. (NASDAQ: YGYI), closed the day's trading session at $6.30, up 1.61%, on 60,038 volume with 579 trades. The average volume for the last 3 months is 214,770 and the stock's 52-week low/high is $3.167/$16.25.

Recent News

chart

Canopy Rivers Inc. (TSX.V: RIV) (OTC: CNPOF)

The QualityStocks Daily Newsletter would like to spotlight Canopy Rivers Inc. (RIV) (CNPOF).

Canopy Rivers Inc. (TSX.V: RIV) (OTC: CNPOF) was featured today in a report by CannabisNewsWire. Individuals hoping to gain exposure to the movement of the markets have two primary options: spend a lot of time and effort researching public companies, or put faith into a fund. A solid investment strategy is key to keeping pace with inflation and reaching your financial goals, but the significant risk and volatility that can come with investing in a small group of companies is a real turn-off for most part-time investors.

Canopy Rivers Inc. (TSX.V: RIV) (OTC: CNPOF) is the venture capital investment platform of Canopy Growth Corporation (TSX:WEED, NYSE:CGC).

Canopy Rivers is a unique investment and operating platform structured to pursue investment opportunities in the emerging global cannabis sector. Canopy Rivers collaborates with Canopy Growth to identify strategic counterparties seeking financial and/or operating support. Headquartered in Toronto, Canada, Canopy Rivers has developed an ecosystem of complementary cannabis operating companies operating throughout the cannabis value chain.

Canopy Rivers, in collaboration with Canopy Growth, has established a diverse portfolio of cannabis industry investments that includes domestic and international companies, licensed producers, late-stage licensed producer applicants, pharmaceutical formulators, brand developers and distributors, retail networks, and technology and media platforms. Investments are customized for each counterparty and include a balanced mix of equity, debt, royalty and profit-sharing agreements.

Canopy Rivers’ expanding portfolio includes:

  • Agripharm Corp. (private) is an ACMPR licensed producer, acquired by Canopy Growth in January 2017. In November 2017 Agripharm completed a joint venture with globally recognized partners Green House Seeds and Organa Brands. Canopy Growth has sublicensed proprietary technology, trademarks, genetics, know-how and other intellectual property from Agripharm to distribute the suite of Green House and Organa Brands products across the country, when permissible.
  • CanapaR Corp. (private) owns 80% of CanapaR Italy, a Sicily-based company focused on developing and commercializing Italy’s local hemp cultivation industry through its partnership with the renowned Department of Agriculture at the University of Catania and its rapidly building extraction capabilities for the production of organic CBD oil. CanapaR Italy’s outsource farming model with local Sicilian farmers and its university partnership will provide it with a low-cost source of organic CBD oil, which is increasingly used as an input into new commercial products in the growing health and wellness industries.
  • Civilized Worldwide Inc. (private), is a media and lifestyle brand with offices in New Brunswick and California that embraces and highlights modern cannabis culture. Civilized aims to engage the millions of productive, motivated people who choose to enjoy cannabis responsibly as part of their lifestyle. Reaching 2+ million unique visitors per month, North America-wide, Civilized produces engaging content for and about people who enjoy cannabis responsibly.
  • James E. Wagner Cultivation Ltd. (TSXV:JWCA) was founded in 2007 by third generation agricultural and cannabis cultivators. JWC is the first entirely aeroponic producer of cannabis in Canada, and its patent-pending aeroponic production technology, called GrowthStormTM, allows for perpetual harvesting and improved yields. The company was issued a license to cultivate from Health Canada in January 2017 and a subsequent sales license in March 2018.
  • LiveWell Foods Canada Inc. (TSXV:LVWL) was established in 1993 as a nutritional lifestyle company, and operates in the production of fresh produce and food technology. The company’s O-Hemp division distributes bulk and retail hemp products through its existing channel partners. LiveWell entered into a strategic agreement with Canopy Rivers and Canopy Growth in April 2018.
  • PharmHouse (private) is a joint venture between Canopy Rivers and the principals and operators of leading North American greenhouse produce companies. PharmHouse has arranged to acquire a newly built 1.3-million-square-foot greenhouse located in Leamington, Ontario.
  • Radicle Cannabis Inc. (private) is an ACMPR-licensed cannabis company based in Hamilton, Ontario backed by a management team that brings extensive experience in regulated industries, retail distribution, tobacco and pharmaceutical development, as well as Award-winning cannabis horticulturist breeders and medical professionals.
  • Solo Growth (TSXV:ALZ) is a new cannabis retail concept that will operate locations under the name “YSS by Solo,” relying on the expertise of a management team comprised of founding shareholders, senior officers and board members of Solo Liquor Stores Ltd., a leading Canadian liquor retailer. Solo Growth was established through a recapitalization of Aldershot Resources Ltd.’s corporate structure that will allow the company to execute a new retail-focused cannabis business strategy.
  • Spot Therapeutics Inc. (private) is an applicant that was acquired by Canopy Growth in August 2017 to solidify its Maritimes expansion strategy and less than four weeks later Canopy Growth signed a supply MOU with the New Brunswick government. Canopy Rivers purchased the property and entered into a long-term lease and committed funding agreement with Canopy Growth.
  • TerrAscend Corp. (CSE:TER) cultivates high-quality cannabis in an indoor hydroponic facility, backed by a strategic investor boasting a strong background in the pharmaceutical space and an extensive portfolio of specialty pharma assets.
  • Vert Mirabel (private) is a joint venture that was established in December 2017 between Canopy Rivers, Canopy Growth, and Les Serres Stephane Bertrand. Bertrand is a large-scale greenhouse operator located in Mirabel, Quebec, and the largest grower of pink tomatoes in the country. With guidance and assistance from Canopy Growth, the greenhouse has been upgraded and retrofitted for cannabis production and was licensed by Health Canada in May 2018.

As the company’s portfolio continues to develop, each constituent benefits from opportunities to collaborate with Canopy Growth and among themselves. Canopy Rivers believes this formula results in an ideal environment for innovation, synergy and value creation for Canopy Rivers, Canopy Growth and across the entire Rivers ecosystem.

Canopy Rivers is led by an experienced team of qualified financial and technical professionals with deep industry experience and relationship networks. The company’s acting CEO and chairman is Bruce Linton, CEO of Canopy Growth and founder of Tweed Marijuana.

Canopy Rivers Inc. (TSX.V: RIV), closed the day's trading session at $4.52, up 0.89%, on 527,831 volume with 1,247 trades. The average volume for the last 3 months is 595,150 and the stock's 52-week low/high is $2.40/$11.82.

Recent News

chart

The Green Organic Dutchman (TSX: TGOD) (OTC: TGODF)

The QualityStocks Daily Newsletter would like to spotlight The Green Organic Dutchman (OTC: TGODF).

Cannabis-focused research and development company The Green Organic Dutchman Holdings Ltd. (TSX: TGOD) (OTCQX: TGODF) this morning announced its entry into a multi-year extraction services contract with Valens GroWorks Corp. (CSE: VGW) (OTCQB: VGWCF), a licensed provider of cannabis products and services specializing in various proprietary extraction, distillation, cannabinoid isolation and purification technologies. Also today, CannabisNewsWire released a report featuring the company, detailing how, increasingly, novices and seasoned traders alike are turning to mutual funds for their stability and ease of use.

The Green Organic Dutchman (TSX: TGOD) (OTC: TGODF), whose principal location is in Hamilton, Ontario, produces farm grown, organic, pesticide-free medical cannabis in small batches using all natural, organic craft growing principles. TGOD is licensed under the Access to Cannabis for Medical Purposes Regulations (ACMPR) to cultivate medical cannabis. The company carries out its principal activities producing cannabis pursuant to the provisions of the ACMPR and the Controlled Drugs and Substances Act (Canada).

Committed to becoming the global leader in delivering organic cannabis solutions that enhance people’s lives, TGOD consistently adheres to the highest levels of excellence. Its world-class management team includes a proven group of leaders with outstanding executive and operational experience specific to consumer packaged goods, consumer products, cannabis and finance industries.

TGOD is positioned as one of the highest quality and most cost efficient cannabis producers in Canada by leveraging innovative technology and low-cost power solutions. It holds one of the largest land packages under a single ACMPR license in Canada, providing future cannabis Agri-park style development and opportunities for joint ventures, licensing and distribution partners. Its industry leading alliance partners include Eaton, Ledcor Group and Hamilton Utilities Corp.

Eaton is the second largest power management company in the world and promises to supply innovative and cost effective power solutions to meet TGOD’s growing demands. Construction management is supplied by Ledcor, Canada’s second largest multidisciplinary construction company and a pioneer in the Green Building Industry. An alliance with Hamilton Utilities Corp allows TGOD to reduce its power costs from $0.13 per kWh to less than $0.05 per kWh. Greenhouse design is provided by Larssen Greenhouse, whose 25-plus years of experience in building some of the most modern and sophisticated greenhouses in the industry will provide TGOD with state of the art, climate-controlled hybrid greenhouse solutions.

Canada is quickly becoming a hub for cannabis investors with over $1.3 billion raised by Canadian companies to date. There are 58 licensed producers to service a population of 36 million and only two organic producers. TGOD, which holds licenses in Ontario and Quebec, is strategically located in both provinces that together claim 22 million Canadians as residents. Another estimated 57 million people live next door in six U.S. bordering states.

The Canadian cannabis market currently has a massive supply demand gap, which makes TGOD’s expansion plans even more important to investors. These plans include a combined build-out capacity of 970,000 square feet, allowing TGOD to produce 116,000 kg annually of organic cannabis. Upon completion, Phase One in Hamilton, Ontario, which is fully funded, will provide 150,000 square feet of growing capacity capable of producing up to 14,000 kg of cannabis or $112 million in revenue at $8 a gram.

The company’s Quebec expansion will be constructed on a recently secured 75-acre property near Montreal. This new property has a planned expansion of 820,000 square feet capable of producing 102,000 kg of organic cannabis. The first phase of this expansion is underway and construction is expected to be completed by the end of 2018. Quebec’s first phase will consist of 220,000 square feet capable of producing 22,000 kg of cannabis. Two additional expansion phases will add 250,000 square feet (26,000 kg of cannabis) and 350,000 square feet (54,000 kg of cannabis). Power costs remain exceptionally low for both facilities with access to all other needed utilities available and close by.

TGOD also plans to gain a share of the burgeoning cannabis oils market which by Q1 2017 accounted for 49 percent of all cannabis sold in Canada under the ACMPR, up from only 27% in Q2 2016. TGOD has ordered a purpose-built extraction laboratory with an estimated commission in Q4 of 2017. This is a commercial-scale CO2 extraction unit capable of processing up to 12,000 kg of raw material per year and producing approximately $170 million worth of organic cannabis oils. Raw cannabis oil provides a significant downstream manufacturing opportunity into several potential recreational market verticals including edibles, beverages, topicals and concentrates.

Data from the Canadian ACMPR Market Trends report indicates a rising number of consumers will continue to seek out healthier, less conspicuous ways to consume cannabis, ensuring sales of organic cannabis oil products remain brisk. Organic cannabis products demand a significant premium compared to non-organic products and the demand keeps growing.

Plans to take the company public are underway with an initial public offering (IPO) slated for January 2018. In November, the company raised $13 million in equity financing and in March closed a $27 million non-brokered private placement. Another $20 million is currently being raised before the IPO in January, which will be utilized for expansion plans.

TGOD is uniquely positioned between the medical and recreational cannabis industry since Canada is scheduled to legalize cannabis for all adults in mid-2018. As of August 2017, TGOD has 2,400 shareholders. Established in 2012, TGOD’s motto, “Making Life Better,” can be seen in its strategic partnerships, top quality management team, and dedication to organic farming and principles.

To learn more about the company and how to invest, contact TGOD directly at financing@tgod.ca

The Green Organic Dutchman (OTC: TGODF), closed the day's trading session at $3.272, up 2.89%, on 810,119 volume with 1,327 trades. The average volume for the last 3 months is 1,155,433 and the stock's 52-week low/high is $1.607/$7.894.

Recent News

chart

TransCanna Holdings Inc. (CSE: TCAN)

The QualityStocks Daily Newsletter would like to spotlight TransCanna Holdings Inc. (CSE: TCAN).

TransCanna Holdings Inc. (CSE: TCAN) was featured today in the 420 with CNW by CannabisNewsWire. The House Judiciary Committee in Kentucky voted on Wednesday (March 6) to pass a bill that would legalize medical cannabis in the state. The bill will now be sent to the Rules Committee of the Assembly. House Bill 136 was co-sponsored by 43 members out of the 100 members in the entire lawmaking chamber. This bill intends to create a Department for Alcoholic Beverage and Cannabis Control. This agency will then design a medical cannabis program for the state.

TransCanna Holdings Inc. (CSE: TCAN) through its subsidiaries specializes in assisting clients who are cannabis farmers and manufacturers get recognized by end consumers who in turn purchase their products. TransCanna offers or will be offering services to support almost every aspect of the cannabis-related eco-system; from branding and design, to transportation and distribution, to marketing and sales.

California’s legalized adult-use recreational marijuana market opened for business January 1, 2018. The state’s Bureau of Cannabis Control is responsible for regulating all commercial activities in the state including cultivation, distribution and transportation. Moving cannabis products in the California marketplace is extremely challenging due to municipal and state laws and regulations, which can differ among cities and counties. Since cannabis remains illegal under federal law, Department of Transportation regulated companies are barred from participating in the market, which means companies looking to excel in the sector must hold a state-issued distributor license from the Bureau of Cannabis Control.

TransCanna has already entered into an Intellectual Property Rights and Royalty Agreement for the Track & Trace software platform required by the state of California. TCM Distribution, the operating company managed by TransCanna, has received a transportation and distribution permit from the city of Adelanto and a temporary transportation and distribution permit from the state of California. TransCanna has also executed a land lease to build a 10,000-square-foot transportation and distribution facility in Adelanto.

TransCanna is strategically creating a distribution network throughout California that places its facilities no further than a three-hour drive from most any client. The company is in the process of leasing or purchasing properly licensed and permitted warehouses strategically located throughout California along with new secure trucks, sprinter vans and/or armored vehicles.

TransCanna plans to create its own portfolio of branded products for the cannabis and hemp sectors. The company’s management team intends to translate the skills, knowledge and experience gained from a combined 60 years of branding and marketing experience in the music, professional sports and alcohol industries into TransCanna and the cannabis industry.

As part of the “TransCanna Way,” the company intends to manage most aspects of the supply chain from upper end procurement, branding, transportation and distribution, to marketing and sales.

Leading TransCanna as its CEO and chairman is James Pakulis, who has three decades of experience working with public and private entrepreneurial companies in a variety of emerging and high-growth sectors. He is formerly the president and a director of Lifestyle Delivery Systems Inc. (CSE: LDS) (OTCQB: LDSYF), a vertically integrated cannabis-related entity operating in California. Pakulis was chairman and CEO of General Cannabis Inc. which from 2010 to 2012 owned WeedMaps. Pakulis oversaw the company’s growth from zero to over $16 million in annual revenue in less than 24 months.

The company’s strategic advisors include individuals with extensive experience in branding, marketing, sales, distribution, production and supply chain management.

For additional information, call: (604) 609-6199

TransCanna Holdings Inc. (CSE: TCAN), closed the day's trading session at $3.25, up 6.91%, on 247,150 volume with 183 trades. The stock's 52-week low/high is $0.769/$3.27.

Recent News

chart

Supreme Cannabis Company Inc. (TSX.V: FIRE) (OTC: SPRWF)

The QualityStocks Daily Newsletter would like to spotlight Supreme Cannabis Company Inc. (OTC: SPRWF).

The Supreme Cannabis Company, Inc. (TSX: FIRE) (OTCQX: SPRWF) (FRA: 53S1) today announced that the Company has signed a letter of intent ("LOI") with Malta Enterprises, the economic development agency of Malta. Also today, CannabisNewsWire released a report featuring the company, detailing how, increasingly, novices and seasoned traders alike are turning to mutual funds for their stability and ease of use. Additionally, the company was highlighted in an article examining how the latest development amid marijuana’s growing acceptance as a mainstream market is taking it into the upper echelons of society.

Supreme Cannabis Company Inc. (TSX.V: FIRE) (OTC: SPRWF), is committed to providing premium brands and products that reflect the company’s knowledgeable customers, passionate employees, and culture of innovation. Supreme Cannabis’ mission is to grow the world’s best cannabis and become a leader in the global industry. The company calls its Toronto Venture Exchange stock symbol FIRE “a testament to our passion for cannabis and our obsession with quality.”

Supreme Cannabis believes the world is ready to follow Canada’s lead by ending the 100-year cannabis prohibition and, as Canada’s only coast-to-coast premium cannabis producer, the company sees itself at the center of this global shift.

In August 2018, Supreme Cannabis uplisted its shares to the to OTCQX market in the U.S., where the company trades under the ticker symbol SPRWF. The following month Supreme reported record Q4 revenues of CAD$3.55 million, a 71-percent increase over the previous quarter. Supreme Cannabis also recorded revenue of CAD$8.85 million for its fiscal year ended June 30, 2018, placing it among publicly traded Canadian cannabis companies with the highest reported revenue in their first four quarters of sales.

“As a result of the successful execution of our strategy, we have generated significant revenue growth both for the quarter and the year-end period,” Supreme Cannabis CEO Navdeep Dhaliwal stated in a news release. “We look forward to building on this growth as we expand domestically and internationally.”

The company’s growth strategy includes key industry agreements, such as its CAD$12 million supply agreement with Tilray Inc. (OTC: TLRY), a global leader in cannabis research, cultivation, processing and distribution. The agreement calls for Supreme to supply Tilray with dried cannabis for support of medical cannabis patients in Canada for the period of one year.

Another key component is the company’s wholly owned 7ACRES subsidiary. The 7ACRES cultivation facility, one of the first 40 federally licensed cannabis producers in Canada, is focused on building a core competency in scaled cannabis production, which will give 7ACRES the needed flexibility to maintain leadership in the industry as the Canadian market grows and matures. Though 7ACRES is Supreme Cannabis’ flagship brand and only currently operating business unit, the company will continue to identify new opportunities to grow its portfolio of companies and build innovative cannabis businesses throughout the world.

7ACRES operates from a 342,000-square-foot cultivation facility in Kincardine, Ontario, and has been federally licensed since 2016. Current capacity is 13,333 kilograms dried cannabis annually, with plans to ramp up production by mid-2019 to a rate of 50,000 kilograms per year.

Supreme Cannabis seeks to differentiate 7ACRES from other licensed cannabis producers by producing premium quality product sustainably at scale. “Craft quality, commercial scale” is a slogan the company uses, and the Kincardine greenhouse employs state-of-the-art technology and cultivation best practices to strive toward that goal. Supreme identifies the quality of the 7ACRES product as the company’s primary strength and says a shared “passion for the plant” is the driver of company culture. Six Canadian provinces have signed supply agreements with Supreme, a fact the company credits to the high quality of 7ACRES cannabis.

Its customers, Supreme Cannabis management says, are informed and discerning regarding cannabis, and they value a premium brand that respects their product knowledge. The company believes its high regard for customers, premium product quality, and mass cultivation capability has allowed Supreme Cannabis to emerge as Canada’s preeminent premium cannabis producer. In the Canadian cannabis market, the company has established 7ACRES as a premium brand that’s distributed coast-to-coast and commands premium pricing. The 7ACRES brand is already listed as premium cannabis product in all provinces that disclose their cannabis listing categories, and 7ACRES on average wholesales for up to one-third higher in price than other brands in the Canadian cannabis market.

To further its distribution, in the medical cannabis market Supreme Cannabis has partnered with several Canadian cannabis retailers including Aurora Cannabis, Emerald Health Botanicals, Namaste, Zenabis, and others. The company’s investment portfolio also includes an equity position and long-term global distribution partnership with Medigrow, based in Lesotho, targeting the export of medical cannabis oil for the international market.

Supreme Cannabis seeks to make the company an innovator in the cannabis sector regarding design of cultivation facilities and development of operation excellence metrics. The management team is confident that the 7ACRES flagship brand, the company’s proprietary technology and products, and the company’s culture of passion for cannabis will deliver consistent long-term shareholder value.

Supreme Cannabis Company Inc. (OTC: SPRWF), closed the day's trading session at $1.60, up 3.90%, on 870,702 volume with 1,068 trades. The average volume for the last 3 months is 521,291 and the stock's 52-week low/high is $0.85/$2.04.

Recent News

chart

Golden Developing Solutions, Inc. (DVLP)

The QualityStocks Daily Newsletter would like to spotlight Golden Developing Solutions, Inc. (DVLP).

Golden Developing Solutions, Inc. (OTC PINK: DVLP) ("DVLP" or the "Company"), an emerging leader in the Cannabis and CBD industries, is proud to announce the completion of its acquisition of Infusionz, LLC (CBD Infusionz), a manufacturer of CBD based products. CBD Infusionz offers it's broad product line through it's website, https://www.cbdinfusionz.com/, retail outlets and contract manufacturing agreements.

Golden Developing Solutions, Inc. (DVLP), an emerging leader in ancillary software and the cannabidiol (CBD) products marketplace, provides business services and/or products supporting the cannabis industry including an online retail business for CBD, hemp oil and health/wellness related products.

Global acceptance of cannabis and related CBD products continues to increase as North America advances toward favorable legislation. Canada legalized recreational cannabis in October 2018, and the United States has 30 states and the District of Columbia allowing either recreational or medical cannabis, or both. Voters in four additional U.S. states will consider marijuana initiatives on the November 2018 ballot. The global legal cannabis market is projected to reach USD$146 billion by the end of 2025, with a greater acceptance of medical cannabis products as a driving factor, according to Grand View Research.

DVLP is taking advantage of consumer demand for CBD products through its wholly owned Pura Vida Vitamins, LLC subsidiary, which recently launched a direct-to-consumer website (www.PuraVidaVitamins.com) and commenced sales of Pura Vida branded products. Pura Vida merchandise includes hemp and CBD-related products and other products focusing on health and lifestyle which are available through established wholesale and distribution channels. In addition, a line of CBD pet supplements and other products are in development.

DVLP recently acquired “Where’s Weed” (Layer Six Media LLC DBA “Where’s Weed”) and its primary asset, WheresWeed.com. Where’s Weed is an American cannabis technology company known for connecting medical and recreational cannabis users with trusted local marijuana businesses in their communities. As a rapidly growing community-based online resource for cannabis consumers with a host of user-friendly services, Where’s Weed offers a sophisticated mobile app with strong traction and powerful growth potential as the North American legal cannabis market continues to expand exponentially.

WheresWeed.com has a large and expanding reach with nearly 3 million pageviews per month. In addition, the WheresWeed mobile app, available in both iOS and Android, has been downloaded over 80,000 times, proving to be complementary to DVLP’s objective to capitalize on the massive growth curve in the marijuana space.

“The huge flood of new growers and producers is likely to create oversupply in the near term, narrowing margins for major producers,” says DVLP CEO Stavros Triant. “However, this should actually increase the net number of new consumers in the marketplace, further reinforcing the enormous growth potential for hub service providers in the space that are situated on high-traffic internet real estate, which is exactly how we view the Where’s Weed property.”

The company’s move into the lucrative C-store snack market was solidified with a material purchase order for CBD oils from a major distributor specializing in the snack foods and accessories to the convenience store and gas station market. The order represents significant progress as DVLP gears up its ready-made snack distribution strategy for its CBD products.

“We are extremely excited about the launch of our CBD product line with this distributor,” Triant states. “The C-Store strategy dovetails perfectly with our direct marketing strategy through our primary online retail channel, and we have indications from the distributor that, if this initial test order goes well, successive Purchase Orders could be significant and underpin strong sales growth in Q1 2019.”

Golden Developing Solutions, Inc. (DVLP), closed the day's trading session at $0.0195, up 9.00%, on 5,049,671 volume with 207 trades. The average volume for the last 3 months is 1,959,411 and the stock's 52-week low/high is $0.0122/$0.14.

Recent News

chart

Therma Bright, Inc. (TSX.V: THRM) (OTC: THRBF)

The QualityStocks Daily Newsletter would like to spotlight Therma Bright, Inc. (OTC: THRBF).

Therma Bright, Inc. (TSX.V: THRM) (OTC: THRBF) was featured today in the 420 with CNW by CannabisNewsWire. The House Judiciary Committee in Kentucky voted on Wednesday (March 6) to pass a bill that would legalize medical cannabis in the state. The bill will now be sent to the Rules Committee of the Assembly.

Therma Bright, Inc. (TSX.V: THRM) (OTC: THRBF) is a medical device technology provider focused on addressing dermatological needs in the multi-billion-dollar cosmeceutical industry. The company’s effective, non-invasive and pain-free skin care is based on proprietary technology which has received Class II medical device status from the U.S. Food and Drug Administration.

Therma Bright’s portfolio includes products, devices and treatments that have both cosmetic and medicinal or therapeutic benefits, such as for relief of pain, itch and inflammation resulting from more than 20,000 types of insect and marine life bites and stings, including bees, wasps, hornets, mosquitos, black flies and jellyfish.

The Company’s current focus is to market its products online through various social media networks, and to eventually re-establish relationships with major North American and Global retailers.

Products

The company currently has two products on the market and another in the research and development phase:

InterceptCS™ is a thermal therapy device for the treatment and prevention of cold sores caused by the herpes simplex Type 1 virus*. Symptoms typically include sores around the mouth and lips which InterceptCS™ treats by application of controlled topical heat with no risk of burning the skin. When used at the first sign of an oncoming cold sore application of InterceptCS™ can prevent symptoms from developing. Infrared energy and light from the device penetrate the skin killing cells infected with the virus.

InterceptCS™ is available without prescription and comprises a battery powered ergonomic hand-held unit and a disposable single-use treatment activator. Therma Bright has completed prototyping of multi-use activators for InterceptCS™. The company plans to bring to market 5, 10 or 20 multi-use activations at prices that will offer customers greater value than the current single-use activator.

The other Therma Bright product currently under development is TherOZap™, a next generation thermal therapy device powered by the company’s core technology, which is approved by the FDA as a Class II medical device for the relief of the symptoms of insect bites. Therma Bright is testing a new easier-to-use prototype of the device for effectiveness against Zika virus and other diseases carried by mosquitos. Once the technology proves effective, Therma Bright intends to seek regulatory approvals and extend the prototype enhancements to a new commercial version of TherOZap™.

Cannabis

Therma Bright is also conducting research and development on a unique thermal therapy device that would incorporate medical grade cannabis or cannabidiol (“CDB”) sourced from hemp as a cream or gel to provide relief of back, knee and other joint pain. In preparation, the company has incorporated a wholly owned subsidiary to hold any technology for use or application of cannabis. Once approvals are secured, the company plans to sell the device through licensed cannabis producers or retailers across Canada and in international markets where use of cannabis has been legalized. The company has initiated trademark and patent protection for its thermal therapy technology incorporating medical cannabis. Therma Bright has indicated it will seek an acquisition to help further development of this product.

Market Opportunity

A report by market intelligence firm Mordor Intelligence put the global cosmeceuticals market at a value of nearly US$47 billion in 2017 and projects it to be worth more than $80 billion by 2023, growing at a rate of almost 9.5 percent annually. Medical research estimates that somewhere between 20 percent and 40 percent of the population suffer occasional cold sore outbreaks. In Canada those figures would mean five to 10 million people, and in the U.S. some 40 million to 80 million, with recurring cold sores, representing a substantial potential market for Therma Bright.

Management

Rob Fia serves as Therma Bright chairman and CEO. Fia has extensive contacts in the investment community and the financial sector as well as knowledge of various Canadian stock exchange listing processes and requirements. His 18 years in the investment business has included equity research and advising promising early stage companies on corporate finance. Therma Bright CFO Victor Hugo is a senior financial analyst at Marrelli Support Services Inc., for which he provides CFO, accounting, regulatory compliance, and management advisory services to companies listed on the TSX, TSX Venture Exchange and other Canadian and US exchanges.

**Based on double blind placebo study, the InterceptCS™ is approved by Health Canada for the claim “For prevention of cold sores when used within 3 hours of the onset of the prodrome.” The InterceptCS™ is not approved by the United States FDA or any claim of clinical indication, clinical efficacy, and/or cure or prevention of disease.

Therma Bright, Inc. (OTC: THRBF), closed the day's trading session at $0.0278, even for the day. The average volume for the last 3 months is 5,750 and the stock's 52-week low/high is $0.0099/$0.29.

Recent News

chart

Cannabis Strategic Ventures, Inc. (NUGS)

The QualityStocks Daily Newsletter would like to spotlight Cannabis Strategic Ventures, Inc. (NUGS).

Cannabis Strategic Ventures Inc. (OTC: NUGS), a company focused on supporting entrepreneurial growth in the legal cannabis sector, offers personnel solutions to equip cannabis industry purveyors with the staffing resources that they need to achieve continued growth. Serving all vertical layers of the cannabis industry, Cannabis Strategic Ventures customizes its staffing services to each company’s individual needs, servicing cultivators, manufacturers, dispensaries and others in the cannabis marketplace.

Cannabis Strategic Ventures, Inc. (NUGS), headquartered in Los Angeles, California, is focused on supporting entrepreneurial growth within the fast-growing legal cannabis sector. Through a selective portfolio of subsidiaries, Cannabis Strategic Ventures offers outsourced personnel solutions tailor-made to match the growth dynamics of cannabis cultivators, manufacturers, dispensaries and other cannabis marketplace participants. The company also pursues investment opportunities in the areas of real estate, cultivation, extraction, distribution, packaging, dispensary operations, and branded products within the cannabis space.

The legalization of adult-use sales in California is expected to create nearly 99,000 cannabis industry jobs in the state by 2021, representing about a third of all cannabis jobs nationwide, and 146,000 jobs overall when indirect and induced efforts are considered, according to Arcview Market Research. By 2021, direct cannabis industry employment will top 291,500 FTE jobs, with a total employment effect of nearly 414,000 FTEs across all legal cannabis states, according to the report.

Cannabis Strategic Ventures believes its staffing capabilities will be in a similar state of demand. The company in April 2018 completed a definitive agreement to acquire Worldwide Staffing Group, Inc., which booked approximately $1.5 million in revenues in 2017.

Worldwide will operate within Cannabis Strategic Ventures as an independent and separate wholly owned subsidiary providing strictly non-cannabis related employment and staffing services. As Worldwide continues to expand its operations in general clerical and administrative, marketing, accounting, and other verticals, Cannabis Strategic Ventures will leverage the subsidiary’s expertise to expand its business operations further into the cannabis staffing arena, with an emphasis on the California markets.

Cannabis Strategic Ventures’ BudHire™ subsidiary is an outsourced employment service specifically designed to meet the needs of growing cannabis-related business operations, utilizes a proven recruiting formula to match the most qualified candidates to a broad spectrum of cannabis-related jobs. Under the BudHire™ brand, Cannabis Strategic Ventures offers temporary, seasonal, permanent staffing solutions, as well as professional employment organization services and human resources consulting to the cannabis industry.

Cannabis Strategic Ventures portfolio also includes Pure Applied Sciences Inc. and its brand “PureOrganix™,” a line of high quality concentrate, organic and pure cannabis oils that conform with Current Good Manufacturing Practices (cGMP) and meet FDA guidelines for Active Pharmaceuticals Products (API). The acquisition includes all intellectual properties, including formulations and technologies, and related accessories of Pure Applied Sciences.

Cannabis Strategic Ventures Pure Applied Sciences subsidiary, has a cannabis concentrate extraction services agreement with CP Logistics LLC (“CPL”), a wholly owned U.S. subsidiary of Sunniva Inc. (CSE:SNN) (OTCQX:SNNVF). Under this agreement, CPL will perform white label services producing high quality, ultra-purified cannabis extracts out of its Sun-Oil Facility in Cathedral City, California, for Pure Applied Sciences under the Pure Organix brand name.

The management team at Cannabis Strategic Ventures believes there is incredible opportunity to carve-out and control specific industry niches, to create unique cannabis consumer branded products, and to expand into other sub-sectors of the cannabis marketplace.

Cannabis Strategic Ventures, Inc. (NUGS), closed the day's trading session at $1.65, off by 1.27%, on 56,160 volume with 86 trades. The average volume for the last 3 months is 124,135 and the stock's 52-week low/high is $1.02/$5.94.

Recent News

chart

VIVO Cannabis Inc. (TSX.V: VIVO) (OTC: VVCIF)

The QualityStocks Daily Newsletter would like to spotlight VIVO Cannabis Inc. (VVCIF).

VIVO Cannabis Inc. (TSX.V: VIVO) (OTC: VVCIF) was featured today in the 420 with CNW by CannabisNewsWire. Individuals hoping to gain exposure to the movement of the markets have two primary options: spend a lot of time and effort researching public companies, or put faith into a fund. A solid investment strategy is key to keeping pace with inflation and reaching your financial goals, but the significant risk and volatility that can come with investing in a small group of companies is a real turn-off for most part-time investors.

VIVO Cannabis Inc. (TSX.V: VIVO) (OTC: VVCIF) is a globally licensed, cost efficient producer of premium quality, organic, standardized medicinal cannabis. One of the earliest licensed medical marijuana producers under Canada’s federally-controlled Access to Cannabis for Medical Purposes Regulations (ACMPR), VIVO has five years of operating experience in the burgeoning medical marijuana space through its flagship operation, ABcann Medicinals, Inc. The company recently received its Health Canada license to produce medical cannabis oils and is working toward production of saleable, extracted, finished products that will lead to a final inspection allowing sales of its oils.

“Receipt of the license to produce cannabis oils is a major milestone in our pursuit to provide our medical cannabis patients with additional product formats that can be precisely dosed. The expansion and innovation of our product lines are a top priority for the Company as we continue to serve the needs of our customers, and we anticipate strong demand for our cannabis oil products,” VIVO CEO Barry Fishman said.

VIVO owns and operates a fully functioning 14,500 square foot facility in Napanee, Ontario, which is being doubled in size to produce 1,400 kg of cannabis per year. The company’s expansion plans include adding a seasonal greenhouse and a hybrid, multipurpose facility, capable of producing 31,000 kg of cannabis per year between the two facilities, to be constructed on 65 acres it already owns near the Napanee facility. This additional location is properly zoned with existing infrastructure in place for an eventual 1.2 million square feet of production space.

VIVO has built a reputation over the years for its best-in-class standardized approach to growing cannabis that includes the absence of pesticides and a computer monitored growing technique that provides a consistent, pharmaceutical-grade with high yields. The company’s custom, scalable growing chambers with proprietary lighting can be replicated anywhere in the world, leading to lower production costs. This technique has helped it record a customer retention rate of 94.7 percent alongside 30 percent month-over-month customer growth. When combined with VIVO’s current yield rate, which it has measured at roughly 100 percent greater than the industry average, the company has constructed a strong foundation upon which to build a sizable presence in the global cannabis industry.

This global growth potential is illustrated by VIVO’s partnership with Israel’s Syqe Medical, producer of the world’s first selective-dose pharmaceutical grade medicinal plant inhaler. After visiting VIVO’s production facility, Perry Davidson, founder of Syqe Medical, noted that the company’s production technologies put it “in a class with the best in the world” in its ability to produce standardized pharmaceutical grade cannabis.

VIVO’s recent acquisition of Harvest Medicine Inc. represents further progress toward the company’s goal of becoming a vertically integrated medical cannabis company. Harvest Medicine is one of the fastest growing medical cannabis clinics in Canada – adding over 1,200 new patients monthly from a single location – with an aggressive expansion plan and a patient-focused approach that perfectly aligns with VIVO’s philosophy of quality and innovation.

VIVO’s seasoned management team, board of directors and advisory board features well over a century of combined industry experience. Fishman, who has over 20 years of experience as a business leader, previously served as CEO of both Teva Canada and Taro Canada, as vice president of marketing at Eli Lilly Canada, and as past chair of the Canadian Generic Manufacturers Association. He most recently served as CEO of international specialty pharmaceutical company Merus Labs.

Notably, VIVO also has access to the ‘Father of Cannabis Research’, Raphael Mechoulam, PhD, through its board of advisors. An organic chemist and professor of medicinal chemistry at the Hebrew University of Jerusalem, Mechoulam was the first scientist to isolate both cannabidiol (CBD) and tetrahydrocannabinol (THC). He has received more than 25 prestigious academic awards, including the Rothschild Prize in Chemical Sciences and Physical Sciences in 2012.

With more than 65 acres of growth capacity, a healthy cash balance to fund upcoming construction efforts, steady sales growth, industry-leading yield rates and an established operations team in place, VIVO is well positioned to compete in the rapidly expanding Canadian cannabis industry and beyond.

VIVO Cannabis Inc. (VVCIF), closed the day's trading session at $0.74239, off by 3.84%, on 353,386 volume with 183 trades. The average volume for the last 3 months is 387,325 and the stock's 52-week low/high is $0.413/$1.79.

Recent News

chart

Earth Science Tech, Inc. (ETST)

The QualityStocks Daily Newsletter would like to spotlight Earth Science Tech, Inc. (ETST).

Earth Science Tech Inc. (OTCQB: ETST), an innovative biotech company based in Florida, is actively pursuing a dual listing of its common shares on the Canadian Securities Exchange (“CSE”). In December 2018, ETST engaged the counsel of Fasken, a full-service law firm with offices in Canada and worldwide, to assist with the process, including preparing and filing the required documentation (http://nnw.fm/vk7aI).

Earth Science Tech, Inc. (ETST) is an innovative biotechnology company operating in the fields of hemp cannabinoid (CBD), nutraceutical, pharmaceutical and medical device research and development. Earth Science Tech offers the highest purity and quality, full-spectrum, high-grade hemp CBD (cannabidiol) oil on the market. Made using the supercritical CO2 liquid extraction process, the company’s CBD oil is 100 percent natural and organic. Earth Science Tech has partnered with the University of Central Oklahoma and DV Biologics Laboratory to conduct research and development projects that scientifically support and advance the healthcare benefits of its high-grade hemp CBD oil.

Earth Science Tech Inc. currently has three wholly owned subsidiaries focused on developing its role as a world leader in the CBD space and expanding its work in the pharmaceutical and medical device sectors. These subsidiaries include:

  • Earth Science Pharma, Inc., which is committed to development of low cost, noninvasive diagnostic tools, medical devices, testing processes and vaccines for sexually transmitted infections and/or diseases. Earth Science Pharmaceutical CEO and chief science officer Michel Aubé is leading the company’s research and development efforts. The company’s first medical device, MSN-2, is a home kit designed for the detection of STIs, such as chlamydia, from a self-obtained gynecological specimen. Earth Science Pharma is working to develop and bring to market medical devices and vaccines that meet the specific needs of women.
  • Cannabis Therapeutics, Inc. (“CTI”), which is poised to take a leadership role in the development of new, leading-edge, cannabinoid-based pharmaceutical and nutraceutical products. CTI is invested in research and development to explore and harness the medicinal power of cannabidiol. The company holds a provisional application patent for a CBD product that is focused on developing treatments for breast and ovarian cancers.
  • KannaBidioiD (“KBD”) provides a wide variety of products geared toward the recreational space of cannabis. KBD’s unique Kanna and CBD formulation is sold and distributed in CBD-infused edibles and vapes/e-liquids products. Kanna and CBD synergistically enhance one another, providing optimal relaxation, an uplifting sensation, enhanced focus and the added benefit of assisting with nicotine reduction therapy.

Earth Science Tech celebrated a significant, developmental year during 2017 by sharing its achievements in a condensed end-of-year report. Among the report’s highlights are the implementation of a development plan for the coming three years, which includes expanding into Canada and opening new manufacturing and shipping facilities. Of particular interest is the acquisition of Canna Inno Laboratories Inc., a company headquartered in Montreal, Quebec, Canada, which gives Earth Science Tech access to Canadian government grants offered to innovators in the pharmaceutical industry. ETST has also launched development of proprietary prophylactic therapies utilizing cannabidiol (CBD) to treat various forms of breast cancer.

In October 2017, ETST announced it is cooperating with the Clinique SIDA Amité (AIDS Friendship Clinic) for a mini-clinical trial, the last trial needed before the MSN-2 device, designed for the detection of STIs, enters molecular diagnostic trials. And in November 2017, the company began pre-launch human trials on a new CBD formula to fight against the U.S. opioid epidemic. The new formula, expected to decrease cravings and the negative effects of withdrawal in addicts, is based on industrial hemp CBD mixed with a known natural ingredient proven to help increase dopamine levels. ETST’s medical devices will first be launched in Vietnam, Djibouti and Morocco while the company awaits regulatory permission to enter the North American market.

The company expects to up-list to the OTCQB in early 2018, which management believes will attract well-funded institutional investors and pave the way to becoming the next billion-dollar-in-capitalization company on the OTC markets. Other highlights include completion of the company’s Scientific Advisory Council with a team of recognized scientists, the launching of several CBD-infused edible products and entry into the medical devices market through collaborative partnerships.

Earth Science Tech has signed a collaborate agreement with Laboratories BNK Canada, a private laboratory that will conduct the clinical studies necessary for MSN-2 medical device-related services to meet regulatory requirements. ETST has confirmed the MSN-2 device’s ability to detect chlamydia, and is working to validate similar results for gonorrhea, both highly infectious diseases that often have permanent consequences for patients. ETST will also add testing for trichomoniasis and a complete body fluid panel to detect the different serotypes of the human papillomavirus (HPV) that causes cervical cancer. These additions will help the company create sales opportunities in the global market for diagnostic testing of STDs that Transparency Market Research has indicated will grow to $108 billion by 2019.

Cannabis Therapeutics is in the development stage of two cannabinoid-based pharmaceutical drugs and three cannabinoid-based nutraceutical products targeting a variety of ailments such as anxiety, depression, triple negative breast cancer, and fatty liver disease, among others. Research into the benefits of the non-psychoactive cannabinoid molecules found in the cannabis plant is supported by ETST’s International Application for Provisional Patent titled “Cannabidiol Compositions Including Mixtures and Uses Thereof,” which was filed on October 8, 2015. Cannabis Thera’s R&D efforts are concentrated on developing CBD-based drugs and nutraceutical products and in working to integrate the CBD molecule with existing generic drug molecules to create more efficient medications with fewer and less severe side effects. A report in Hemp Business Journal predicts the CBD consumer market will grow to $2.1 billion by 2020, while other industry experts expect an increase to almost $3 billion by 2021. A recent report by Statista projects the U.S. consumer market for cannabinoid-based pharmaceuticals could reach $50 billion by the year 2029.

The management team at Earth Science Tech brings decades of invaluable experience to the nutraceutical, dietary supplement field as well as the life sciences sectors. Nickolas S. Tabraue, who serves as the president, director and chief operating officer, is an industry veteran with extensive knowledge of supplements, retail management, customer service and sales expertise. He is joined by CEO and CSO Dr. Michel Aubé, a microbiologist whose scientific research in sexually transmitted infections, cancer and stem cell biology has been widely published in several prestigious medical journals. Sergio Castillo, chief marketing officer, and Gabriel Aviles, chief sales officer, bring a wealth of marketing and sales experience to Earth Science Tech, which is complemented by Issa El-Cheikh, Ph.D., and his 25 years in the international finance, accounting, planning and execution of large scale transactions in the public and private sectors.

Earth Science Tech’s products include CBD, a natural constituent of hemp oil derived from hemp stalk and seed. EST offers CBD in the form of vitamins, minerals, herbs, botanicals, personal care products, homeopathies, functional foods and other products delivered in such forms as capsules, tablets, soft gels, chewables, liquids, creams, sprays, powders and whole herbs. Earth Science products can be found at retail stores throughout the United States and are available for purchase through the internet.

Earth Science Tech, Inc. (ETST), closed the day's trading session at $0.7349, off by 0.01%, on 39,431 volume with 27 trades. The average volume for the last 3 months is 31,153 and the stock's 52-week low/high is $0.421/$2.45.

Recent News

chart

Green Hygienics Holdings Inc. (GRYN)

The QualityStocks Daily Newsletter would like to spotlight Green Hygienics Holdings Inc. (GRYN).

As the regulatory framework has changed dramatically over the past few years, the number of companies entering the cannabis sector has increased exponentially. In 2017 alone, there were 28,000 companies active in the field in the United States (http://nnw.fm/JiMU7). Growth continued throughout 2018, when the legal marijuana industry reached $10.4 billion and created over a quarter of a million jobs (http://nnw.fm/4luBN). Green Hygienics Holdings Inc. (OTCQB: GRYN) is already capitalizing on its proprietary cultivation technique. New developments have turned the company into a science-driven cultivation leader as it employs aeroponics-based techniques.

Green Hygienics Holdings Inc. (GRYN) is a full-scope, premium cannabis cultivation company targeting the high-end medical and adult-use recreational market. With more than 25 years of experience in agricultural science and innovation, Green Hygienics is establishing itself as a leader in the advancement of science-driven cannabis cultivation systems. The company will grow by generating revenues from the sales of premium grade cannabis products, developing and licensing valuable IP, making strategic acquisitions, and creating trusted global consumer brands.

The company has integrated and is developing its own IP assets related to proprietary systems and apparatus, software, algorithms and custom-engineered hardware. This provides ultimate efficiencies in a commercially controlled cultivation environment. Utilizing the advantages of hybrid-aeroponics, Green Hygienics creates a sterile growing environment that produces consistent, high-quality product while maintaining the lowest possible carbon footprint. The company utilizes state-of-the-art, quality-controlled commercial cultivation methodology to assure production of pharmaceutical-grade cannabis at much higher yields and greatly reduced costs.

Hybrid-aeroponics produces quality cannabis faster than traditional methods since it doesn’t require natural sunlight or soil and can be operational and produce plants anywhere. Plants grown under aeroponic conditions receive water and nutrients directly to their roots via a fine mist in a controlled environment, dramatically reducing spoilage while keeping the product organic and the environment pest-free. The plants are given the exact amount of nutrients and moisture precisely when needed. Green Hygienics maintains ultimate control over every aspect of this cultivation process, which allows the company to operate with conservation of natural resources in mind. The technology that uses 90-95 percent less water and does not require the use of pesticides or fungicides.

Additionally, the company’s state-of-the-art engineered, controlled environments include electrical, mechanical and HVAC designs that meet mandatory fire and energy codes while improving energy efficiency significantly.

Through these practices, Green Hygienics is establishing itself as a leader in the advancement of science-driven cannabis cultivation systems. The company continues to develop and incubate software as well as engineer hardware to provide additional control over the commercial cultivation method. The company’s science-based approach reveals any growth anomalies before the human eye can see them. This makes it possible to monitor all facets of production, identify cultivation problems based upon scientific data, and implement immediate corrective action, if needed.

The future of commercial cannabis cultivation hinges on using science to control the growing environment in order to remain competitive and deliver a premium grade of product on a consistent basis. The company holds a competitive advantage through its ability to produce premium cannabis products at a significantly lower cost per gram than direct competitors and others in the cannabis industry.

Innovations within the sector that create efficiencies and successful brands will become highly valued. Green Hygienics and its forward-thinking management team are constantly studying the market dynamics of the cannabis industry in North America and abroad while actively pursuing possible expansion opportunities. The company is headquartered in Las Vegas, Nevada and establishing operations in San Diego, California, targeting the $5 billion California cannabis market.

Green Hygienics Holdings Inc. (GRYN), closed the day's trading session at $0.51, off by 1.92%, on 34,378 volume with 19 trades. The average volume for the last 3 months is 26,153 and the stock's 52-week low/high is $0.061/$0.61.

Recent News

chart

Wildflower Brands Inc. (CSE: SUN) (OTCQB: WLDFF)

The QualityStocks Daily Newsletter would like to spotlight Wildflower Brands Inc. (WLDFF).

Vancouver-based Wildflower Brands Inc. (CSE: SUN) (OTCQB: WLDFF) on Friday detailed its plans to complete a private placement of units at a price of $C0.54 per unit for gross proceeds of up to $1.75 million. To view the full press release, visit: http://nnw.fm/L8Pkf.

Wildflower Brands Inc. (CSE: SUN) (OTCQB: WLDFF) is a public cannabis company developing and designing brands that focus on plant-based wellness and health products. Wildflower markets its full-spectrum CBD products to retailers in the health and wellness space throughout the United States and in legal cannabis markets in accordance with regulations marketing its THC and CBD products.

Headquartered in Vancouver, British Columbia, Canada, Wildflower employs a unique and holistic business model that encompasses research and development, manufacturing, distribution, marketing and retail. First launched in 2012 as a private company with a cannabis-focused brand, Wildflower went public in 2014 and has since reached numerous significant milestones in its drive to create brands that work in synergy toward becoming a global wellness brand leader.

Gathered within the growing family of Wildflower brands are the following entities:

  • Wildflower Wellness is known for its reputable brand, uncompromising quality and mission to connect people with the healing power of plants. Wildflower Wellness offers CBD vaporizers, capsules, tinctures, soaps and topicals that are backed by a 100 percent satisfaction guarantee. Wildflower Wellness offers a full lineup of full spectrum CBD extract infused products made in the U.S. in Wildflower’s GMP facilities which are always third-party lab tested for quality assurance and accurate labeling.
  • King Extracts is a California-based company focused on cannabis technology and delivery systems. The King Recharge is a discreet, 97mm small, rechargeable vaporizer with a sleek pocket-sized charging and storage case. King concentrates are clean and sophisticated blends made from CO2 extractions that are fractionally distilled for clarity and purity with proprietary terpenes blended in to deliver a robust, full-flavor profile. King products are available at 26 select, regulated retail dispensaries in California.
  • Exclusive is a dispensary of high-quality cannabis products and accessories serving the city of Los Angeles, California. The company enjoys a close association with select hospital oncology departments and community programs.

Using the slogan “Plants Heal,” Wildflower’s distribution network in the U.S. includes 200+ retailers in Washington state and 20+ retailers in New York City. Wildflower has also partnered with Retail Worx to establish shop-in-shop retail locations in the heart of New York City which pairs nicely with the introduction of Wildflower into existing Bridges General’s stores in New York City and San Francisco. Through this partnership with Retail Worx, Wildflower by Bridges General stores will have exclusive product offerings in addition to the full lineup of existing Wildflower Wellness CBD products. Distribution in other U.S. markets includes 80+ wellness and healthcare practitioners with a total distribution of over 300 stores nationwide.

Wildflower holds 14 California cannabis licenses that cover recreational and medical cannabis cultivation, manufacturing, distribution and retail/delivery in the jurisdictions of California state and the city of Los Angeles. Opportunities to activate these licenses creates the phenomenal potential of driving significant revenues while minimizing risk. Expansion plans into Canada are underway with discussions centered on retail acquisitions and Wildflower launching into over-the-counter market with its CBD product line. Global expansion is a key part of Wildflower’s strategy with initial plans aimed at specific international markets where regulatory hurdles are less restrictive.

In December 2018, Wildflower began on-demand, legal and licensed cannabis delivery services to adult consumers in the Los Angeles area and has hired dozens of full-time delivery drivers to accommodate this unmet need. Wildflower has partnered with leading technology and logistics company Eaze.com to help route deliveries efficiently, manage inventory and comply with California law. Providing legal, licensed delivery services helps to ensure that all adults including those with mobility challenges and limited access to transportation services can purchase high quality, legal cannabis products.

Wildflower’s direct-to-consumer online store sales have shown an organic growth. The Company recently achieved over 300 percent growth in online sales since January 2018 with annualized revenues exceeding $1 million for online sales only, marking the ninth consecutive quarter of increased revenue.

Core Team

William MacLean is the founder and CEO of Wildflower Brands Inc. His involvement in all aspects of the business from product R&D to manufacturing setup has led the Company to its current success. MacLean is a seasoned sales professional with over 20 years of experience in various industries from advertising and marketing to medical sales. While in the advertising and marketing space, his clients included major brands including: Bell, Remax, BC Hydro, and Royal Bank.

CFO Stephen Pearce is a director and officer of a number of public companies in the resource sector. His professional experience as a practicing attorney is primarily in corporate and securities work. Pearce’s academic background includes an honors bachelor’s degree in economics from York University, in which he focused specifically on corporate finance. Pearce obtained a law degree from the University of British Columbia.

Alfred Kee, COO, is a business technology leader with over 15 years of experience in building high performing teams at small startups to large enterprises. With foundations in running large scale business critical technology and user experience product management mindset, Kee excels at guiding teams to deliver business value with agility. His knowledge and experience were honed while working with Electronic Arts, KPMG, CenturyLink, Cisco and Apple, as well as a string of successful startups. Lee brings a global perspective having lived and worked through parts of the U.S., Canada, Europe and Asia.

Creative Director Amy Yamamura is a founding member of Wildflower and has been a driving force behind the Company from the start, creating the Wildflower brand. After receiving a bachelor’s degree in communications from Boston University, Yamamura returned to Tokyo to develop her career in TV as an international business correspondent coordinating collaborative projects between top creators around the world and corporations. Yamamura’s unique experience in working closely with successful Japanese brands like UNIQLO has given her exceptional eyes for branding a company.

Wildflower Brands Inc. (WLDFF), closed the day's trading session at $0.4045, off by 7.24%, on 5,394 volume with 15 trades. The average volume for the last 3 months is 14,360 and the stock's 52-week low/high is $0.009/$1.139.

Recent News

chart

City View Green Holdings Inc. (CSE: CVGR)

The QualityStocks Daily Newsletter would like to spotlight City View Green Holdings Inc. (CVGR).

City View Green Holdings Inc. (CSE: CVGR) (formerly Icon Exploration Inc.) (the "Company" or "City View Green") trading through the facilities of the Canadian Securities Exchange ("CSE") under the symbol "CVGR" is pleased to announce that Budd Hutt Inc., a retail focused cannabis company which City View Green owns a 19.99% stake in, has appointed Mr. Craig Belcher as CEO.

City View Green Holdings Inc.'s (CSE: CVGR) (formerly Icon Exploration Inc.) primary objective is to create a well-diversified company focused on assessing and potentially acquiring targets in the cannabis industry. Icon Exploration recently signed a formal share exchange agreement relating to its proposed acquisition of privately held City View Green (“CVG”), a vertically integrated cannabis company incorporated under the laws of Ontario, Canada. CVG’s application to Health Canada for an A6ccess to Cannabis for Medical Purposes Regulations (“ACMPR”) license is now at the in-depth review stage of the licensing process.

CVG is preparing a 40,000-square-foot growing facility near Toronto to produce pharmaceutical-grade cannabis once its ACMPR license is granted. About half of the facility will initially be outfitted with state-of-the-art LED lighting, HVAC and dehumidification systems, and automation technologies to optimize the quality, safety and consistency of cannabis production. About 4,000 square feet will be devoted to an extraction laboratory featuring an ultra-efficient CO2 supercritical extraction process with plans to include ethanol extraction technology in the future.

Another 4.3 acres remains available for future construction of up to 125,000 square feet of grow and extraction space. Production plans include producing high quality edible products, distillates, and water-soluble products for the rapidly expanding CBD-infused (cannabidiol) beverage market.

Management

Icon and CVG have assembled a talented team that includes a Master Grower with cannabis-industry experience to manage indoor grow operations and an extraction expert whose expertise in developing and launching new products was honed while working in Washington state’s cannabis sector. Having gained experience in the Washington state market the extraction expert has a number of brand ideas and recreational cannabis products that became popular in the Washington market as well as a number of in-licensing branding opportunities available to CVG. CVG has also negotiated an agreement with a private company seeking 37 retail cannabis licenses in Alberta, Canada, that provides a reciprocal exchange of shares, product, shelf space and distribution lines. Early discussions with various entities in Europe to arrange an off-take agreement for CBD oils and extracts are also underway.

Market Opportunity

The Canadian medical cannabis market has steadily been growing with an average 10 percent increase in patients each month. Now that the Canadian federal government has legalized recreational cannabis for adult users nationwide, analysts project a compound annual growth rate of nearly 78 percent from 2018 to 2021, reaching an estimated $3 billion by 2021, ArcView Market Research reports. One study from Deloitte pegged the potential economic impact of legalized medical and recreational marijuana in Canada – including transportation, licensing fees and security – at more than $22 billion over the coming years. Health Canada’s most recent data show that sales of cannabis extracts grew 961 percent in the second quarter of 2017, compared to an 89 percent increase in growth of dried cannabis during the same period.

City View Green Holdings Inc. (CSE: CVGR), closed the day's trading session at $0.19, off by 9.52%, on 293,042 volume with 76 trades. The average volume for the last 3 months is 2,257,195 and the stock's 52-week low/high is $0.145/$0.465.

Recent News

chart

Marijuana Company of America Inc. (MCOA)

The QualityStocks Daily Newsletter would like to spotlight Marijuana Company of America Inc. (MCOA).

Warren Buffett, ‘the Oracle of Omaha’, famously said, “A truly great business must have an enduring ‘moat’ that protects excellent returns on invested capital.” By a moat, the legendary investor meant some competitive advantage that would sustain the enterprise by protecting its market from rival firms. A patent, like the one issued to Marijuana Company of America Inc. (OTCQB: MCOA), can work just as well, he said (http://nnw.fm/8ZzVK).

Marijuana Company of America Inc. (OTC: MCOA) (the “Company”) are pioneers in the cannabis industry going back to 2009 when Don Steinberg, MCOA’s CEO, founded the first marijuana company ever to trade on a U.S. stock market, Medical Marijuana Inc. Since then, Don and his partner, Charlie Larsen, have formed Global Hemp Group and Marijuana Company of America. They have experienced the shift of legislation first hand, not only for the legalization of marijuana but also the emerging hemp-based CBD products.

The CBD market is growing exponentially and consequently the founders of MCOA have constructed their business model around the development of industrial hemp-based CBD products. The industrial hemp plant can be used to produce products that are carbon neutral or even carbon negative. It is one of the longest, strongest natural fibers on earth, used as a building material that is free of mold, pesticide-resistant, and fire proof. Hemp has also been described as a “super food,” which provides additional business opportunities. No part of the plant is left unused and the Company’s overall strategy is to take advantage of every profit center from farm to the multiple valuable finished products.

The cannabis and hemp industries are experiencing unprecedented growth that is expected to continue for many years as these industries are now accepted globally and continue to mature and expand. North American consumers spent $6.7 billion on legal cannabis products in 2016, up 34% from 2015’s $5 billion. This trend is widely expected to explode at a 27% compounded annual growth rate to reach $22.6 billion by 2021, according to ArcView Market Research.

The company offers investors the opportunity to be on the forefront of cannabis and hemp innovation through cultivation, processing in the legal cannabis and industrial hemp sectors. The Company’s business model includes producing a diverse portfolio of synergistic business segments that provide value to its shareholders. Its vertically integrated business model and distribution platforms are positioned to capture market share by developing recognizable and valuable brands.

Under the MCOA umbrella, wholly owned subsidiary hempSMART™, Inc. is committed to bringing high quality CBD-based products to the market through its affiliate marketing program. Through hempSMART, MCOA’s strategic approach to the distribution of products is through a networking architecture geared to maintain customer loyalty and capture market share. The patent-pending product “hempSMART Brain,” is designed to revolutionize the safe and effective support of healthy brain function. The brand new product, HempSMART DROPS, is a full-spectrum CBD tincture formulated with hemp and fractionated coconut oils. The hempSMART marketing team has decades of experience, and is well positioned to take the hempSMART brand to a global audience.

Marijuana Company of America Inc. (MCOA), closed the day's trading session at $0.0118, off by 2.48%, on 12,952,263 volume with 330 trades. The average volume for the last 3 months is 13,625,856 and the stock's 52-week low/high is $0.0115/$0.0499.

Recent News

chart

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


QualityStocksTwits

QualityStocksTwits is your stock tracking service portal to Twitter's universe of stock picks, commentary and research.

Visit Portal


The QualityStocks Sponsored News


The QualityStocks DailyNetwork Sponsors

ActionStockPicksAgressive StocksBetting On Wall StreetCannabisNewsWireGot Stocks?Got Stock Tips?Green Car StocksGreen Energy StocksGreen On The StreetHomeRunStocksMissionIRMissionIR MediaMissionPRMissionSMRNetworkNewsWireQualityStocks MediaQStocksQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsStock BeatsStocks To Buy NowTerrificStocksTiny GemsTip.usTouchdownStocksDaily ToutTraderPower

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.